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Background: Fall-related injuries in older adults result in serious consequences to 
individuals and health care system, especially with the increasing aging population. The 
purpose of this study was to (1) describe medication prescription patterns within one year 
prior to fall-related injuries; (2) identify medication classes prescribed within 30 days prior to 
the injury that were associated to fall-related injury; and (3) examine the association between 
fall-related injuries and continuous use or new initiation of most commonly prescribed 
medications.   
Methods:  Studies used administrative health care data in Ontario. Study 1 described the 
frequency of medications prescribed to older adults within one year before they had fall-
related injuries. Study 2 and 3 were case-control studies. The cases were older adults aged 66 
years and older, who had a fall-related injury between January 2010 and December 2014. 
Controls were older adults with same age, sex and residence area as the cases. In study 2, 
medications prescribed to both groups were recorded and logistic regression was conducted 
to examine the association between medications and injuries. Study 3 defined continuous use 
as medication use for more than 90 days and new initiation was defined as starting a 
medication within 30 days prior to injuries. Logistic regression was conducted to examine the 
association between injuries and continuous use or new initiation of medications.  
Results: Within one year before the injury, 27.2% of older adults were prescribed 
antidepressants, 25.0% opioids, 16.6% anxiolytics, and 36.4% were prescribed 5-9 
medications and 41.2% were prescribed 10 or more medications. After adjustment for sex, 
age group, residence area, income and number of medications prescribed, laxatives, 
antibiotics and bronchodilators were identified to increase the risk of fall-related injury. 
Continuous use of antidepressants, anticholinesterases and antithrombin agents and new 
initiation of antidepressants, opioids and cephalosporins were reported to increase the risk for 
injuries. 
Conclusion: Findings of this thesis uncovered several medication classes such as antibiotics 




continuous use and new initiation of particular medication classes were associated with 
injuries. Well-designed prospective cohort studies are needed to provide more convincing 
evidence. 
Keywords 





Summary for Lay Audience 
Fall-related injuries in older adults can result in serious harm to individuals and health care 
system, especially with the world increasing aging population. The purpose of this study was 
to (1) describe the types of medications older adults used within one year before they 
experienced a fall that resulted in an injury; (2) identify if medications prescribed within 30 
days before the fall that were associated with increased the risk of fall-related injury; and (3) 
find out whether continuous use of a medication or start of a new medication were associated 
with increased the risk of fall-related injury. Data was extracted from databases hosted by 
IC/ES. We recorded the medication prescribed to older adults and calculate the percentage of 
medication users. Our result was, within one year before the injury, 27.2% of older adults 
used antidepressants, 25.0% opioids, 16.6% anxiolytics, 36.4% used 5-9 different 
medications and 41.2% used 10 or more different medications. Then we used case-control 
study design and logistic regression to find out the possibility of having fall-related injury 
when an older adult took certain kind of medication. We also identified the possibility of 
having fall-related injuries when an older adult took certain kind of medication for over 90 
days or start a new medication within 30 days prior to the injury. After taking sex, age group, 
residence area, income level and number of medications used into consideration, we found 
that users of laxatives, antibiotics and inhaled medications for asthma were more likely to 
have fall-related injury. Continuous use of antidepressants, medications for dementia and 
blood thinners and new initiation of antidepressants, opioids and cephalosporins were 
associated with increased risk for fall-related injuries. Findings of this thesis uncovered 
several medication classes such as antibiotics and bronchodilators that were associated with 
increased risk of fall-related injury, which was not reported in previous studies. It was also 
suggested that continuous use and new initiation of particular medication classes were 
associated with injuries. Well-designed cohort studies are needed in the future to provide 
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Chapter 1  
1 Introduction 
1.1 World Aging Population  
Ageing is an inevitable process of living and, conventionally, it is measured by 
chronological age where people who are 65 years or older are referred to as “older 
adults” (Orimo et al., 2006; World Health Organization [WHO], 2020). Although the 
ageing process is not homogeneous across the world due to different genetics, lifestyles, 
overall health and environment, most developed countries in the world have accepted the 
definition of older adults as people who are 65 years or older. In recent years, steady 
progress has been made in reducing mortality in the early and middle years of life, which 
led to the dramatic increase of ageing population globally. Better sanitation, 
improvements in housing, education and nutrition, advances in preventive and therapeutic 
medicine all contribute to a longer life expectancy (Kirkwood, 2017). 
In 2019, the world population aged 65 years and older was almost 700 million (World 
Bank, 2020), which constitutes 9.1% of the total population. According to WHO report, 
there were 900 million people 60 years and older in 2015, but in 2050, the number is 
expected to increase to 2 billion. For people who are 80 years and older, the world -wide 
numbers will be increasing from 125 million in 2015 to 434 million in 2050 (WHO, 
2018a). Population trends are similar in Canada and the province of Ontario. The number 
of people aged 65 and over in Ontario is projected to almost double from 2.4 million 
(16.9% of population) in 2018 to 4.6 million (23.4%) by 2046 (Ontario Ministry of 
Finance, 2020). 
 An ageing world brings many opportunities as well as challenges, not only for older 
adults and their families, but for the society as well. A longer life provides a chance for 
pursue of new lifestyles and more contribution to families and communities. But if the 
extended lifespan is dominated by chronic comorbidities, reduced mobility and declined 
mental capacity, the implications of longer life for older adults and the society are rather 
negative. Falls in older adults are one of the major public health concerns because falls 
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can lead to loss of functional ability and independence, increased admissions or re-
admissions to health care facilities and hospitals, and inestimable medical and social 
costs (Alexander & Hunter, 2017; Masud & Morris, 2001).  
1.2 Falls and Fall-Related Injuries in Older Adults 
A fall is defined by WHO as “an event which results in a person coming to rest 
inadvertently on the ground or floor or other lower level” (WHO, 2018b). Nearly one 
third of older adults fall every year globally (Chang et al., 2010; Tinetti et al., 2006), but 
the rate of falls varied in different regions, with a prevalence of  about 20% in  China 
(Wu & Ouyang, 2017), Japan (Tanimoto et al., 2014)  and Canada (Pearson et al., 2014), 
29% in US (Bergen et al., 2016) and 30-35% in European countries (National Institute of 
Prevention and Health Education, 2008; Rapp et al., 2014; Sandmark et al., 2012). The 
rate of falls increases with age, with nearly 50% of older adults who are 80 years and 
older experiencing a fall each year (de Negreiros Cabral et al., 2013; Rubenstein & 
Josephson, 2002).  
Falls are the leading cause of fatal and non-fatal injury in older adults (Bergen et al., 
2016; Public Health Agency of Canada [PHAC], 2014). Falls account for 40% of all 
injury-related deaths (WHO, 2007) and more than 80% of all injury-related hospital 
admissions (Kannus et al., 2006; Peel et al., 2002). Between 30-50% falls result in minor 
injuries, such as bruises or lacerations, while 5-10% of falls lead to serious injuries such 
as fractures or traumatic brain injury (Cameron et al., 2012; Gillespie et al., 2012; 
Goldacre et al., 2002; Health Quality Ontario, 2008; Masud & Morris, 2001; Rubenstein 
& Josephson, 2002). An estimated 7 million older adults in US reported a fall-related 
injury in 2014 (Bergen et al., 2016). In 2017, 8.4 million older adults in Western 
European regions (22 countries including France, Germany, Greece, Italy, etc) sought 
medical attention due to a fall-related injury, and about 54,000 older adults died of fall-
related injury (Haagsma et al., 2020). In 2009-2010, a total of 256,011 Canadian older 
adults reported a fall-related injury, where 35% were fractures, 30% sprains or strains, 
19% scrapes, bruises or blisters, 6% cuts or punctures, 3% dislocations, 2% concussions 
and brain injury, and 5% other injury (PHAC, 2014).  
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Although there is substantial of research published on “fall-related injury”, or “injurious 
fall” or “fall injury”, a lack of standardized definition of a “fall-related injury” has been 
reported repeatedly as a major methodological limitation, especially when comparing 
outcomes of different studies (Lamb et al., 2005; Hauer et al., 2006; Schwenk et al., 
2012). Some studies used fractures, especially hip fracture, as a proxy for the fall-related 
injury (Tanaka et al., 2018; Wong et al, 2020). However, this definition ignores a wide 
range of injuries, such as head and internal injuries, which can also lead to serious 
consequences requiring higher level of care, such as hospitalizations. The continuous 
improvements in healthcare system and enhanced reliability of injury reporting systems 
through administrative databases, identifying fall-related injury based on the healthcare 
service use became a practical and credible way to study this topic (Campbell et al., 
1997; Elley et al., 2008; Schwenk et al., 2012). In this thesis, fall-related injury was 
operationally defined as any injury caused by a fall that resulted in an admission to the 
Emergency Department (ED) or hospital. Different fall-related injury types include: 
superficial injuries, open wounds, fractures, dislocations, sprains or strains of joints and 
ligaments, nerve injuries, blood vessels injuries and injuries to internal organs (Canadian 
Institute of Health Information [CIHI], 2018a; WHO, 2019). 
On an individual level, besides the immediate suffering from a fall-related injury, 
common adverse consequences are fear of falling (Pereira et al., 2020), reduced  quality of 
life (Gill et al., 2013; Boyé et al. 2013), higher possibility of admission to long-term care 
(Gill et al., 2013), prolonged hospital stays (PHAC, 2014), and increased risk of death 
(Skelton & Todd, 2004; Stevens et al., 2006). On a societal level, fall-related injuries 
pose a substantial economic burden to the public health care system. In 2004, the 
estimated cost of fall-related injuries among Canadian older adults was more than $2 
billion Canadian dollars (Scott et al., 2010). Florence and his colleagues reported that, in 
2015, the estimated medical costs related to both fatal and nonfatal falls was 
approximately US $50 billion US dollars. For non-fatal falls, Medicare paid $28.9 billion, 
Medicaid $8.7 billion and private and other payers $12.0 billion. Overall medical 
spending for fatal falls was estimated to be $754 million US dollars (Florence et al., 
2018). In 2006-2007, the direct cost of fall-related injury was estimated at $558.5 million 
in New South Wales, Australia, and the cost of hospital admissions accounted for 84.6% 
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of the total cost (Watson et al., 2011). The financial burden of fall-related injuries is 
substantial and global.  
Despite significant advances in fall and fall-related injury prevention research, increasing 
implementation of fall prevention practices, and enhanced consciousness of individuals’ 
safety and self-protection, the trend of fall-related injuries around the world remains 
unclear. Watson and Mitchell (2011) observed a hospitalization rate due to falls increased 
by 1.7% each year from 1998-2008 in New South Wales, Australia, but the rate of 
fractures resulting from falls declined by −0.4% and the non-fracture rate increased by 
6.1% per year. In 2001-2010, a decreasing incidence was observed in the Swedish older 
adults in younger age groups (65-79 years), with greater decreases in females (14.6% in 
females vs 10.5% in males), while an increasing trend of hospitalized fall-related injuries 
was observed in 80 years and older age group (Nilson et al., 2016), with greater increases 
in males (4.3% in females vs 11.4% in males). Superficial injuries showed greater 
increases than fractures in those aged 80 years and above (Nilson et al., 2016). Even after 
controlling for US population growth, ED visit rates for falls continued to grow (Shankar 
et al., 2017). Between 2003 and 2010, the ED visit rate for falls and fall-related injuries in 
American older adults increased from 60.4 to 68.8/1,000 population. Older adults aged 
75-84 years accounted for the greatest rate increase, with ED visit rates increasing from 
56.2 to 82.1/1,000 population (Shankar et al., 2017). In Canada, the number of older 
adults who reported a fall-related injury increased from 47.2 per 1,000 population in 2003 
to 57.5 per 1,000 population in 2009/2010 (PHAC, 2014).  
Due to rapid growth of aging population around the world, undesirable consequences of 
fall-related injuries and complex trends in different injury types across countries, it is of 
great importance to further research on fall-related injuries so that practical and 
individualized fall prevention protocols could be developed and implemented efficiently.  
1.2.1 Risk factors for falls and fall-related injury 
Unclear trends in the older adult population and increased aging population make fall-
related injury a major health concern. Even after assuming that the falls rates for age and 
gender remain constant overtime, a forecasted 55% increase in the number of older 
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people between 2014 and  2030 in US, would result in 48.8 million falls and 11.9 million 
injuries in 2030 (Bergen et al., 2016), unless there are effective prevention programs 
implemented national wide. A thorough investigation of risk factors and mechanism of 
falls and fall-related injuries is necessary for creating meaningful injury prevention 
programs. 
Fortunately, falling is not a normal part of aging and can be prevented at some occasions. 
Although the present research is about injury, it is inevitable to reflect little deeper into 
immediate cause of injury – the fall. Multiple risk factors are proved to be associated with 
falls and they are categorized as biological, behavioral, environmental and socioeconomic 
(WHO, 2007). Some of the risk factors are difficult to change while others are 
modifiable. Biological risk factors such as age, gender, race and socioeconomic risk 
factors such as low income and education levels, inadequate housing, limited access to 
health and social care are non-modifiable or very difficult to change. But, there are risk 
factors that are potentially modifiable, for example, physical or cognitive alteration d ue to 
aging (biological), excess alcohol use, sedentary lifestyle, intake of multiple medications 
(behavioral), slippery floor or stairs, insufficient lighting or uneven sidewalks 
(environmental).  
Fall-related injury, on the other hand, was often entangled with falls in previous studies. 
Risk factors for fall-related injury have yet to be reported systematically. History of falls 
(Ravindran & Kutty, 2016), psychotropic medication (Haasum & Johnell, 2017; Johnell 
et al., 2017; Yu et al., 2017), anti-hypertensive agents (Shimbo et al., 2016), nutritional 
condition (Sim et al., 2018), multiple chronic diseases (Cartagena et al. 2017), and 
depression (Kvelde et al., 2015; Ravindran & Kutty, 2016) were among the risk factors 
previously reported to be associated with fall-related injury after the age of 65. Both a fall 
or fall-related injury are a result of complex interactions of risk factors requiring 
multifactorial prevention strategies.  
Interventions reported to be effective in lowering the risk of fall-related injuries include 
physical exercise to improve balance (Hill, 2018), managing chronic diseases (Chang et 
al., 2004; Cheng et al., 2018), visual impairment (Reed-Jones et al., 2011), and changing 
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personal behaviors (Larsson et al., 2010). Many countries and health organizations have 
declared the prevention of falls in older adults as an important health priority (Lamb et 
al., 2005; Skelton & Todd, 2004; the Canadian Patient Safety Institute, 2015; WHO, 
2007). It is forecasted that achieving a 20% reduction in falls between 2010 and 2035 
among adults aged 65 years and older in Canada would save 4,400 lives and avoid a total 
cost of $10.8 billion Canadian dollars (Parachute, 2015). 
1.3 Medication Use in Older Adults 
Older adults are the largest consumers of prescription medications worldwide. In US, 
older adults comprised 13% of total population, but accounted for 34% of the prescription 
medication use and 30% of over-the-counter medication use (National Council on Patient 
information and Education, 2020). About 87% of older adults took one or more 
prescription medications, and 36% took at least five medications concurrently (Qato et 
al., 2016). CIHI reported that older adults made up only 17% of the total population in 
Canada, but they accounted for almost 40% of all spending on prescription medications 
and 55% of public drug program spending (CIHI, 2018b).  
Medications play crucial role in older adults’ health by effectively treating the chronic 
diseases, alleviating pain and increasing quality of life. However, physiological changes 
in the aging body and polypharmacy make older adults susceptible to adverse drug 
reactions (ADRs) that could lead to falls and fall-related injury.   
1.3.1 Pharmacodynamics and pharmacokinetics of drugs in an 
aging body 
The premarketing clinical drug trials usually exclude elderly participants, thus the 
pharmacokinetics (i.e., medication’s absorption, distribution, metabolism and excretion) 
and pharmacodynamics (i.e., the physiologic effects of the medication) are unknown or 
unclear in older adults. Research shows that drug absorption is reduced in the older adults 
due to decreased gastrointestinal blood flow, loss of mucosal intestinal surface and 
reduced gastric acidity (Hughes, 1998; Mangoni & Jackson, 2004). Moreover, the 
weakening gastrointestinal movement and slower gastric emptying time increases the 
medication absorption (Mangoni & Jackson, 2004). These are just some complex factors 
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that make it difficult to evaluate the medication absorption in older adults. But there are 
more.  
With advancing age, the total body fat increases 18-36%, while the muscle mass 
decreases by 30% (Vestal, 1997; Thürmann, 2020). These changes result in a prolonged 
half-life (i.e., the time that a medication decreases to half of its starting concentration in 
the body) of lipophilic drugs such as antidepressants, long-acting benzodiazepines and 
antiepileptics. This means that the time medications exert their therapeutic effect and 
adverse effects increases (Hammerlein et al., 1998; Thürmann, 2020). Similarly, the body 
water content in older adults shrinks by 15-20% (Reeve et al., 2015), resulting in an 
apparent decrease in the distribution volume of medications such as digoxin, diuretics 
and lithium (Huang et al., 2012). Dosage reductions must be considered to avoid potential 
toxicity of these drugs (Hammerlein et al., 1998; Cusack, 2004). The serum albumin 
usually declines by 15-20% in frail or malnourished older adults (Cusack, 2004), which 
increases the plasma concentration of free (unbound part to protein) or active fraction of 
some medications. The effect of highly protein-bound medications, such as phenytoin, 
diazepam and valproic acid, in a reduced serum albumin environment is enlarged. 
Usually, there are no abnormal changes in hepatic function indexes as the body ages, but 
the activity of hepatic metabolism of esterase is decreased which results in prolonged 
half-lives of medications such as metoprolol, morphine and verapamil (Kinirons & 
O'Mahony, 2004; Le Couteur et al., 2012). The age-related reduction in liver 
parenchymal cells and a decrease of liver blood flow also affect the liver’s ability to 
metabolize drugs (Kinirons & O'Mahony, 2004; Le Couteur et al., 2012).  A combination 
of these factors further compounds the drug clearance ability in older adults, causing drug 
effect enhancement and more potential for adverse reactions. 
Further, drug excretion in older adults declines due to reduced kidney mass, renal blood 
flow, glomerular filtration rate and tubular secretion rate (Huang et al., 2012). Estimated 
GFR can adequately represent the elimination of drugs through kidney function and the 
dosage of medications can be adjusted according (Reeve et al., 2015). 
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What is more, genetics, lifelong living habits and environmental factors can lead to high 
heterogeneity in pharmacokinetics and pharmacodynamics of drugs among older adults 
(Huang et al., 2012). It is unlikely that a frail 90-year-old man with multiple chronic 
diseases and a robust, healthy 70-year-old man would have the same response to a 
specific drug or dosage. The heterogeneity in later life and reduced homeostasis further 
increase the complexity of managing medication therapy and ADRs in older adults.    
1.3.2 Polypharmacy 
Polypharmacy is defined as concurrent use of multiple medications by a patient. 
However, there is no agreement or standard to the exact minimum number of medications 
that define ‘polypharmacy’, and suggestions vary from 2 to 11 medications (Ferner & 
Aronson, 2006; Masnoon et al., 2017). Although polypharmacy usually refers to the use 
of prescribed medications, it is also necessary to consider the number of over-the-counter 
and herbal supplements used by the patient.  
Older adults often use multiple medications due to co-existence of several chronic 
diseases (Crentsil et al., 2010). Gao and his colleagues (Gao et al., 2018) reported that 
during the study period of 1991-1994 the number of older adults in England who were 
taking five or more drugs concurrently was 1 in 8 (12%), but from 2008-2011, this rate 
increased dramatically to nearly 1 in 2 (49.6%). In 2016, 65.7% of Canadian older adults 
took five or more prescription drugs and 26.5% older adults took ten or more different 
prescription drugs (CIHI, 2018b).  
Although sometimes polypharmacy is deemed necessary and appropriate, it increases the 
potential of drug-drug interactions and risk of ADRs (Weng et al., 2013). Polypharmacy 
also leads to problems with adherence, especially when older adults have visual or 
cognitive impairment (Wimmer et al., 2017). Older adults who receive care from 
different physicians and specialists, and those who fill their prescriptions at different 
pharmacies, can exaggerate the effect of polypharmacy by using medications with similar 
therapeutic purpose or increased dosage (Kuo et al., 2014).    
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Pharmacological changes of drugs in an aging body and polypharmacy predispose older 
adults to an increased risk of falls, injuries, hospital admissions and diminished quality of 
life (Chen et al., 2014; Chung, 2014; Huang et al., 2012; Rowe, et al., 1976; Tan et al., 
2015). Report from CIHI indicate that in 2011, one in 200 Canadian older adults was 
hospitalized as a result of ADRs, and 2.8% of all hospitalizations of older adults were due 
to ADRs (CIHI, 2013). 
1.4 Medications and Fall-related Injury 
Since 1980s, researchers began to pay attention to the association between medications 
and falls. Several observational studies reported that benzodiazepines, antipsychotics 
(most of them were tranquillizers), and tricyclic antidepressants were associated with 
increased risk of falls and hip fracture in older adults (Davie et al., 1981; Macdonald, 
1985; Ray et al., 1987; Tinetti et al., 1988). The concept that drugs might increase the 
risk of falls was first proposed by Cumming and colleagues in 1991. The authors created 
a list of medications that included diuretics and psychotropics (Cumming et al., 1991). In 
2007, van der Velde and colleagues presented a list of drugs associated with increased 
risk of falls according to previous studies, and it was the first time the acronym FRID for 
fall risk-increasing drugs was used (van der Velde et al., 2007). The National Board of 
Health and Welfare (NBHW) in Sweden produced an updated FRID list in 2010, and an 
additional list of medications that cause or worsen orthostatic blood pressure, known as a 
relevant fall risk factor (the Swedish NBHW, 2010). This FRIDs list used Anatomical 
Therapeutic Chemical (ATC) codes proposed by WHO to identify medication classes 
(Appendix A). Although there is no consensus on which medications should be included 
in FRID list, most studies recognize psychotropic medications such as opioids (N02A), 
antiepileptics (N05A), anxiolytics (N05B), hypnotics and sedatives (N05C) and 
antidepressants (N06A) as FRIDs (Axmon et al., 2018; Winter et al., 2016; Zia et al., 
2017).  
FRIDs are important independent risk factors for both falls and fall-related injury and had 
been studied extensively. Psychotropic medications can be defined as a class of drugs that 
can cross the blood-brain barrier and act directly on the central nervous system (CNS) 
(Bloch et al., 2010; Hill & Wee, 2012; Kawakami et al., 2019). Common psychotropic 
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drugs include antiepileptics, anti-Parkinson agents, anxiolytics, hypnotics, antipsychotics, 
antidepressants and drugs used in dementia. A substantial proportion of older adults use 
one or more psychotropic drugs, from 20% of community-dwelling older adults (Du et 
al., 2017; Préville et al., 2001) to nearly 80% of older adults lived in long-term care 
facilities (Galik & Resnick, 2013; Mann et al., 2009). A series of systematic reviews 
conducted in 2018 summarized the association between common medication classes and 
falls, fall-related injuries, and recurrent falls in older adults (de Vries et al., 2018; 
Seppala, Wermelink, et al., 2018; Seppala, van de Glind, et al., 2018). Older adults using 
opioids were 78% more likely to have a fall-related injury (five-study pooled adjusted 
OR [aOR]=1.78, 95%CI [1.54-2.06]; I2=85%). Antidepressants were associated with 
increasing the risk of fall-related injury by 72% (five-study pooled aOR=1.72, 95%CI 
[1.51-1.95], I2=72%). Benzodiazepines were associated with increasing the risk of fall-
related injury by 70% (one study reported aOR=1.70, 95%CI [1.03-2.81]). Older adults 
who used antiepileptics were 43% more likely to have a fall-related injury (two-study 
pooled aOR=1.43, 95%CI [1.10-1.86], I2=0%).  
Hypertension is a very common chronic disease in older adults, with prevalence of 27% 
in people younger than 60 years and 74% in those older than 80 years (Lloyd-Jones et al., 
2005). Antihypertensive drugs are among the most frequently prescribed medications in 
older adults. Canadian Institute for Health Information reported that in 2016, 24.5% of 
Canadian older adults were prescribed angiotensin-converting enzyme inhibitors 
(ACEIs), 23.5% were prescribed beta-blocking agents (BBs), 21.9% dihydropyridine 
calcium channel blockers (CCBs) and 15.7% angiotensin II antagonists (CIHI, 2018b). 
Another study of 4,961 older adults with hypertension showed that 56.6% were 
prescribed renin-angiotensin system (RAS) blockers, 54.2% diuretics, 45.9% BBs, and 
34.2% CCBs.  
Although antihypertensive drugs were not classified as FRIDs, their association with falls 
and fall-related injuries in older adults was studied extensively. Diuretics (C03), BBs 
(C07), CCBs (C08), and RAS inhibitors (C09) are all listed as drugs that may cause or 
worsen orthostatic hypotension in the list produced by Swedish NBHW. 
Antihypertensive drugs can potentially result in fall-related injury, due to syncope or 
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dizziness caused by orthostatic hypotension. However, results of previous studies on 
antihypertensive drugs and fall-related injuries are conflicting. Leipzig and his colleagues 
completed a meta-analysis on the effect of diuretics (Leipzig et al., 1999). They reported 
that furosemide and thiazides were weak risk factors for fall injuries in older adults 
(pooled OR=1.08; 95%CI [1.02-1.16]), while CCBs and ACEIs were not risk factors. 
Another systematic review and meta-analysis conducted by Wiens et al. (2006) suggested 
a lower risk of fractures in older adults using BBs and diuretics (pooled RR=0.86 95%CI 
[0.81-0.92] for diuretics and pooled RR=0.81, 95%CI [0.73-0.89] for BBs), but an 
enhanced risk of fractures in older adults using CCBs (pooled RR=1.96; 95%CI [1.16-
3.30]). For the past forty years, psychotropic medications have been consistently and 
clearly recognized as FRIDs, while the evidence that antihypertensives are also FRIDs 
was less clear. Overall, research had been mainly focused on psychotropic medications 
and antihypertensives’ association with falls and fall-related injuries. 
1.5 Background Summary and Knowledge Gap 
As described, risks for falls are multifactorial. However, research has not produced strong 
evidence on risk factors for fall-related injuries for older adults. Some studies focused on 
specific groups of older adults such as those with vestibular dysfunction (Marchetti, 
2003), or with chronic kidney disease (Kistler et al., 2018), or with lower limb 
amputations (Wong et al., 2016). Other studies focused on specific settings, such as 
hospitals (Fischer et al., 2005), or particular racial group, such as Chinese (Pi et al., 2016; 
Li et al., 2016), Korean (Kim et al., 2018) and Indonesian (Pengpid &Peltzer, 2018). 
Majority of studies reporting the risk factors for fall-related injuries in older adults are 
combined with risk factors for falls. Fall-related injuries lead to high morbidity and 
mortality (McClure et al., 2008), thus it is necessary to study injuries caused by falls 
independently to gather evidence and inform strategies for injury prevention.  
Research on medication use in older adults either focused on older adults in general 
(CIHI, 2018b; Neoh et al., 2017), or on one or two specific classes of medication 
frequently used by older adults such as antihypertensive drugs (Mohd et al., 2012), blood 
sugar lowering drugs (Clemens et al., 2015), sedatives and hypnotics (Kassam et al., 
2006; Tseng et al., 2018), and opioids (Weesie et al., 2020; Wilder-Smith, 2005). A 
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literature review by Peng and colleagues (2019) revealed the need for a comprehensive, 
population-based report on medication use in older adults before they had a fall-related 
injury. It is clear that more knowledge on medication use prior to injury is necessary. 
Logical first step is a descriptive study to determine the patterns and prevalence of 
medication prescribing to older adults before fall-related injury. This study will serve to 
generate future research questions on the association between fall-related injury and 
types, numbers and duration of medication use. 
A clear and complete recognition of risk factors is essential in injury prevention. In 1980, 
William Haddon developed of a systematic analysis for the preventative approaches with 
Haddon “phase-factor” matrix (Haddon, 1980). Although it was originally designed for 
traffic injuries, the matrix was soon adapted for prevention of various types of injuries, 
including fall-related injuries in older adults (Sattin, 1992). Medication use was 
recognized as one of the pre-event host factors for fall-related injuries in older adults and 
thus the prevention focused on limiting excess prescribing of high-risk psychotropic 
medications (Sattin, 1992). However, current research on association between 
medications and fall-related injuries in older adults is limited and confined to 
psychotropic drugs and anti-hypertensive drugs (de Vries et al., 2018; Seppala, 
Wermelink, et al., 2018; Seppala, van de Glind, et al., 2018; Wiens et al., 2006; Zang, 
2013), leaving out a wide range of medication classes commonly prescribed to older 
adults. For example, in developed countries, statins were prescribed to 40-50% older 
adults  (CIHI, 2018b; Chee et al., 2018; Ofori-Asenso et al., 2018), proton pump 
inhibitors to 20-30% older adults (CIHI, 2018b; Kanno, & Moayyedi, 2019), non-steroid 
anti-inflammatory drugs (NSAIDs) to 7% older adults (Wongrakpanich et al., 2018) and 
insulin to 7% older adults (Clemens et al., 2015). Similarly, in 2016, 51.7% older adults 
in Ontario were prescribed with statins, 32.5% proton pump inhibitors. Other medication 
classes were also commonly prescribed to Ontario older adults, for example, 16.6% older 
adults in Ontario were prescribed thyroid hormones, 14.4% biguanides, 14.2% penicillins 
with extended spectrum, and 11.4% fluoroquinolones (CIHI, 2018b). Studies on the risk 
of fall-related injury while using these medication classes are scarce and the results often 
conflicting (Seppala, van de Glind, et al., 2018). Therefore, it is necessary to expand 
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inquiry beyond FRIDs to include more medication classes and explore their association 
with fall-related injury.  
1.6 Purpose of Dissertation 
The overall purpose of this dissertation was to provide a comprehensive evidence on 
medication classes prescribed to older adults prior to their fall-related injuries and 
evaluate their association.  
The purpose of Study 1 was: (a) to provide a comprehensive list of medication classes 
prescribed to older adults within one year prior to their fall-related injuries. The purpose 
of Study 2 was to evaluate the association between fall-related injuries and most 
frequently prescribed medication classes prescribed within 30 days prior to the injuries. 
The purpose of Study 3 was to explore association between continuously used and newly 
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Chapter 2  
2 Medication Prescribed within One Year prior to Fall-Related 
Injuries in Ontario Older Adults 
2.1 Introduction 
Falls are the leading cause of both fatal and non-fatal injury in older adults (Bergen & 
Stevens, 2016). Nearly one third of older adults fall every year (Chang et al., 2010; 
Tinetti et al., 2006). Minor injuries, such as bruises or lacerations, occur in 30-50% of 
falls, while 5-10% of falls lead to serious injuries such as hip fractures or traumatic brain 
injury (Cameron et al., 2012; Gillespie et al., 2012; Goldacre et al., 2002; Health Quality 
Ontario, 2008; Masud & Morris, 2001; Rubenstein & Josephson, 2002). Fall-related 
injuries can also result in adverse consequences such as reduced quality of life (Gill et al., 
2013), higher possibility of admission to long-term care facilities (Gill et al., 2013), and 
increased risk of death (Skelton & Todd, 2004).  
Numerous fall-related risk factors in older adults have been identified through past 
research, specific use of certain medications or combinations of medications in particular 
was reported to be associated with both increased falls and fall-related injury in this 
population (Ambrose et al., 2013; Huang et al., 2012). For instance, psychotropic 
medications and concurrent use of more than four medications have consistently been 
found to increase falls risk in older adults (Hartikainen et al., 2007; Leipzig et al., 1999; 
Park et al., 2015; Woolcott et al., 2009). With increasing knowledge on the association 
between medications and falls or fall-related injuries, certain classes of medications were 
reported repeatedly to be associated with falls and it was van der Velde who first 
proposed the acronym FRID for fall risk-increasing drugs. FRIDs include 
antihypertensive agents, diuretics, antidepressants, analgesics, anti-epileptics, and 
sedative/ hypnotics (van der Velde et al., 2007; The Swedish National board of Health 
and Welfare, 2010) which increase falls and fall-related injuries within older adult 
populations (Bauer et al., 2012; Winter et al., 2016; Zia et al., 2017). 
While previous research has commonly investigated the association between specific and 
known FRIDs, and fall-related injuries (e.g., benzodiazepines (Davies et al., 2018; 
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Donnelly et al., 2017); anti-hypertensive medications (Verma et al., 2018, de Vries et al., 
2018); antidepressants (Kurdyak et al., 2007, Axmon et al., 2018), limited evidence 
currently exists regarding medication classes of other than FRIDs that were prescribed to 
older adults prior to a fall-related injury. Providing a more comprehensive picture of 
medication classes prescribed to older adults before the occurrence of a fall-related injury 
is necessary to expand our knowledge on medications that may induce any fall-related 
injury. Therefore, the purpose of this study was: (1) to describe medication classes and 
numbers of medication classes prescribed to older adults within one year prior to the fall-
related injury; and (2) to describe medication classes prescribed to older adults within one 
year prior to fall-related fractures and fall-related brain injury, as these two types of 
injury are of high prevalence and can cause serious consequences (Court-Brown et al., 
2017; Peterson & Kegler, 2020; Teo et al., 2018) 
2.2 Methods 
2.2.1 Study Design and Setting 
We conducted a population-based, descriptive study of medication classes prescribed to 
older adults (>65 years of age) who experienced at least one fall-related injury between 
January 1, 2010 and December 31, 2014, using Ontario healthcare administrative data 
held by the provincial data steward IC/ES. The extraction of eligible participants in this 
study was conducted by IC/ES analysts, based on a carefully prepared data creation plan 
(DCP, Appendix B). Ontario is the largest province in Canada, with a population of 14.7 
million and 2.6 million older adults over the age of 65 (Statistics Canada, 2020), all of 
whom have access to universal healthcare services. IC/ES is an independent, non-profit 
research institute whose legal status under Ontario’s health information privacy law 
allows it to collect and analyze health care and demographic data. IC/ES is a prescribed 
entity under the section 45 of Ontario’s Personal Health Information Protection Act. 
Section 45 authorizes IC/ES to collect personal health information, without consent, for 
the purpose of analysis or compiling statistical information with respect to the 
management of, evaluation or monitoring of, the allocation of resources to or planning 
for all or part of the health system. Projects conducted under section 45, by definition, do 
not require review by a Research Ethics Board. This project was conducted under section 
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45, and was approved by IC/ES’ Privacy and Legal Office. However, ethics approval for 
this series of studies was required in Western University, and it was obtained from the 
Research Ethics Board at Western University, London, Ontario, Canada (HSREB 
#109335, detailed information was provided in Appendix C).  
2.2.2 Population 
Older adults aged 66 years and older, who experienced a fall-related injury over the study 
period (January 1, 2010 to December 31, 2014), and resided in Ontario, were included in 
this study. A fall-related injury was defined by combining the ICD-10-CA codes 
(Canadian Institute of Health Information [CIHI], 2018a; WHO, 2019a) for falls (W00-
W19) with codes for injury (S00-S99, T00-T14) (Appendix D). To be included, each 
person’s diagnosis necessitated containing at least one W code for falls and at least one S 
or T code for injuries. The Emergency Department visit date for a fall-related injury was 
defined as the index date. Fall-related injuries of interest in this study were: (1) any fall-
related injury, (2) fall-related fracture; and (3) fall-related traumatic brain injury. Fall-
related fracture was identified through presence of at least one specific fracture S code 
(S02, S12, S22, S32, S42, S52, S62, S72, S82, S92, T08, T10, T12, T142) and one W 
code (W00-W19). Fall-related traumatic brain injury was identified by presence of at 
least one specific concussion and brain injury code (S06, S099) and one W code (W00-
W19).  
2.2.3 Data Sources 
We used records arising from several databases held by IC/ES, including: (1) the Ontario 
Drug Benefit (ODB) database, which provides prescription drug coverage data for 
residents over the age of 65, including individuals in long-term care homes (Government 
of Ontario, 2019); (2) the Discharge Abstract Database (DAD), which records 
information on all hospital admissions and discharge diagnosis; (3) the National 
Ambulatory Care Reporting System (NACRS), which captures information on visits to 
emergency departments and community-based ambulatory care facilities; and (4) the 
Ontario Registered Persons Database (RPDB), which contains demographic information 
for Ontario residents. These datasets were linked using a unique encoded identifier, 
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which ensured the confidentiality of personal and health information. We assessed older 
adult comorbidities using the various IC/ES-derived data sets, applying validated case 
definitions, including diabetes, chronic obstructive pulmonary diseases, asthma, 
hypertension, and dementia. Sociodemographic data (i.e., age, sex, and income quintile) 
was extracted from the RPDB, primary diagnosis data arose from both NACRS and 
DAD, and medication prescriptions were drawn from ODB.  
2.2.4 Medication Information   
Medication information extracted from the ODB database used the Drug Identification 
Number (DIN) assigned by Health Canada (Health Canada, 2018). Each DIN uniquely 
identifies the manufacturer, trade name, active ingredients, strength of active ingredients, 
pharmaceutical form and route of administration (Health Canada, 2018). For better 
understanding and comparability with the results of other studies, DIN codes were 
converted and categorized into Anatomical Therapeutic Chemical (ATC) level 5 codes 
(see Appendix E). The ATC classification system was devised by the World Health 
Organization (WHO) to categorize medications based on the system or organ upon which 
they act, as well as their therapeutic and chemical features (WHO, 2019b). In the ATC 
classification system, each medication is classified in a hierarchy with 5 levels. 
Medication use information was reported on the 4th level of ATC codes in this study. 
ATC 4th level is the level used to count number of different medications as it is the level 
which aggregates medications just above their descriptive chemical substance (Krause, 
2008).  
2.2.5 Outcomes 
The primary outcome of this study were medication classes prescribed to older adults 
within one year prior to any fall-related injury, fall-related fractures and fall-related 
traumatic brain injuries. We quantified any fall-related injury and presented pattens in 
medication classes prescribed within the year prior to injury. We also explored 
medication prescription patterns within one year prior to both fall-related fractures and 
fall-related brain injuries. Finally, the number of ATC 4th level medication classes 
prescribed to each older adult within a year was calculated and summarized into four 
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categories: 0-4 medication classes, 5-9 medication classes, 10-14 medication classes and 
15 or more medication classes (CIHI, 2018a). 
2.2.6 Statistical Analysis 
Descriptive analysis summarized the cohort baseline characteristics, such as age, sex, age 
group, and income quintile. Income quintile is a measure of socioeconomic status that 
divides the population living in the same dissemination area into 5 income groups (1 
represents the lowest income; 5 represents the highest income) with approximately 20% 
of the population in each group (CIHI, 2016). The dissemination area was determined 
from the older adults’ residential postal code and statistics Canada Census data (Wilkins, 
2010). Comorbidities (i.e., diabetes, chronic obstructive pulmonary diseases, asthma, 
hypertension and dementia) were also analyzed using descriptive statistics. The fall-
related injury (any injury type) was reported for each year and as a five-year total (2010-
2014). 
The percentage of people prescribed each ATC 4th level medication class was calculated 
by dividing the number of people who were prescribed a certain class within a year prior 
to a fall-related injury (numerator) by the total number of older adults who experienced a 
fall-related injury (denominator). The formulas are listed below. FRI-OA stands for older 
adults who had a fall-related injury. 
Percentage of older adults who were prescribed certain medication class prior to a fall-
related injury=
Number of FRI-OAs prescribed certain medication class
Total numbers of FRI-OAs
 
Percentage of female/male FRI-OAs prescribed Certain Medication Class 
=
Number of Female/Male prescribed certain medication class 
Number of Female/Male FRI-OAs
 
Percentage of different Age Group (66-74, 75-84, 85+) FRI-OA prescribed certain 
medication class =
Number of Age Group FRI-OA prescribed certain medication class




The top 20 medication classes with the highest number of users were summarized as the 
percentage of female and male users, and percentage of different age-group users (i.e., 
66-74, 75-84, 85+). The same analysis was repeated for subgroups of older adults who 
experienced fall-related fractures and fall-related TBIs. The difference between 
percentages of female and male older adults prescribed certain medication classes was 
determined by Wilcoxon rank-sum test and the comparison among different age groups 
was determined by Kruskal-Wallis test. The numbers of different ATC 4th level 
medication classes prescribed to older adults within one year prior to the fall-related 
injuries were counted for each older adult and were categorized into 4 different groups: 0-
4, 5-9, 10-14 and 15 or more medication classes (CIHI, 2018b). All analyses were 
conducted with SAS 9.4 (SAS Institute, 2013). All the SAS codes for extracting and 
analyzing data were provided in Supplementary Content of this thesis. 
2.3 Results 
A total of 288,251 older adults experienced any fall-related injury from 2010 to 2014. 
Fall-related fractures made up 40.0% of all fall-related injuries, superficial injuries were 
23.2%, open wound were 16.3%, traumatic brain injury were 12.1%, sprains and strains 
were 5.0%, other injuries were 3.5%. The mean age was 78.3±7.8 years old and 63.2% 
of the older adults were female. Over three quarters (76.9%) were diagnosed with 
hypertension, 30.5% with diabetes, 26.9% with COPD, 15.8% with dementia and 15.0% 
with asthma (Table 2.1) For number of medications prescribed,  3.5% of the study 
population were not prescribed any medication classes within one year before the injury, 
while 18.9% were prescribed 1-4 different medication classes, 36.4% were prescribed 5-9 
different medication classes, 26.0% were prescribed 10-14 different medication classes 
and 15.2% were prescribed more than 15 different medication classes. Frequency 
distribution of different numbers of medication classes prescribed to older adults prior to 
fall-related injuries was presented in Figure 2.1.  
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Table 2.1 Characteristics of Older Adults who Experienced Fall-Related Injuries in 2010-2014 
 2010 2011 2012 2013 2014 2010-2014 
Age (Mean±SD) 78.7±7.6 78.5±7.7 78.5±7.8 78.1±7.9 77.8±8.0 78.3±7.8 
Age Median 79 79 79 78 78 78 
Total Number 56,203 56,230 55,945 58,950 60,923 288,251 
Age 66-74 (n, %) 18,673 (33.2) 19,296 (34.3) 19,842 (34.8) 22,160 (37.6) 23,813 (39.1) 103,424 (35.9) 
Age 75-84 (n, %) 22,429 (39.9) 22,014 (39.2) 21,551 (38.5) 21,644 (36.7) 21,752 (35.7) 109,400 (38.0) 
Age 85+ (n, %) 15,091 (26.9) 14,920 (26.5) 14,912 (26.7) 15,146 (25.7) 15,358 (25.2) 75,427 (26.2) 
Sex Female (n, %) 36,562 (65.1) 35,976 (64.0) 35,315 (63.4) 36,492 (61.9) 37,656 (61.8) 182,136 (63.2) 
Income Quintile       
1(lowest) 11,687 (20.88) 11,325 (20.22) 11,169 (20.04) 11,668 (19.87) 13,868 (22.80) 59,717 (20.79) 
2 11,525 (20.59) 11,455 (20.46) 11,521 (20.68) 11,953 (20.35) 13,486 (22.17) 59,940 (20.87) 
3 11,134 (19.89) 10,922 (19.50) 10,921 (19.60) 11,480 (19.55) 11,816 (19.43) 56,273 (19.59) 
4 10,887 (19.45) 11,146 (19.90) 11,208 (20.11) 11,920 (20.30) 10,581 (17.40) 55,742 (19.41) 
5 10,737 (19.18) 11,151 (19.91) 10,902 (19.57) 11,712 (19.94) 11,069 (18.20) 55,571 (19.35) 
Comorbidities       
Diabetes (n, %) 16,639 (29.6) 16,926 (30.1) 17,036 (30.5) 18,200 (30.9) 19,161 (31.5) 87,962 (30.5) 
COPD (n, %) 15,388 (27.4) 15,207 (27.0) 15,223 (27.2) 15,781 (26.8) 15,963 (26.2) 77,572 (26.9) 
Asthma (n, %) 8379 (14.9) 8,374 (14.9) 8,283 (14.8) 8,951 (15.2) 9,192 (15.1) 43,179 (15.0) 
Hypertension (n, %) 43,325 (77.1) 43,332 (77.1) 43,197 (77.2) 45,113 (76.5) 46,556 (76.4) 221,523 (76.9) 



















































Numbers of Different Medication Classes
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Complete medication classes prescribed are provided in Appendix F, Table A1. The top 
10 drug classes prescribed within a year before any fall-related injury included HMG-
CoA reductase inhibitors (C10AA), proton pump inhibitors (PPIs, A02BC), angiotensin 
converting enzyme inhibitors (ACEIs, C09AA), beta-blocking agents (C07AB), natural 
opium alkaloids (N02AA), dihydropyridine derivatives (C08CA), biphosphonates 
(M05BA), thyroid hormones (H03AA), glucocorticoids for systematic use (H02AB) and 
benzodiazepine derivatives (N05BA).  
HMG-CoA reductase inhibitors, commonly known as statins and used to treat high 
cholesterol, were the most commonly prescribed medication class, used by nearly half 
(48.5%) of the study population. They were also the most frequently prescribed 
medication class in analyses stratified by sex and age sub-groups (Table 2.2 and Figure 
2.2). More than half (54.8%) of males were using statins before they experienced an all 
cause fall-related injury. In the 75-84 age group, 53.4% used statins and the percentage 
dropped to 42.8% in the group of 85 years and older adults.  
Proton pump inhibitors (PPIs) were the second most commonly prescribed drug class, 
with 34.3% of all older adults. PPIs are usually used to treat gastroesophageal reflux and 
peptic ulcer diseases. For age groups 75-84 and 85 years and older, a slightly greater 
percentage of PPI use was found (36.2% and 36.5% respectively), while the age group 
66-74 years old had somewhat lower prevalence (30.6%).  
Four drug classes for the management of hypertension were noted among the top 10 drug 
classes. ACEIs were prescribed to 33.9% of male and 26.1% females. A higher 
percentage of males were also prescribed beta-blocking agents (Males: 27.8% vs. 
Females: 24.8%). However, agents acting on the renin-angiotensin system (RAS) and 
thiazides were prescribed in higher percentage to females than males (Table 2.2). The 
prescription of agents for treatment of high blood pressure increased with age. The 
percentage of 85 years and older age group prescribed ACEIs (C09AA), beta-blocking 
agents (C07AB), and dihydropyridine derivatives (C08CA) were the highest among the 




Table 2.2 Top 20 Medication Classes Prescribed to Older Adults Prior to a Fall-related Injury, Percentage of Users, 2010-2014 
ATC 
code 
Drug Class Common Use 









C10AA HMG CoA reductase inhibitors High cholesterol 48.5 44.7 54.8 <.01 
A02BC Proton pump inhibitors Gastroesophageal reflux, peptic ulcer disease 34.3 35.8 31.7 <.01 
C09AA ACE inhibitors, plain High blood pressure 29.0 26.1 33.9 <.01 
C07AB Beta blocking agents, selective High blood pressure, heart failure 25.9 24.8 27.8 <.01 
N02AA Natural opium alkaloids Management of moderate to severe pain 25.0 25.0 25.0 0.72 
C08CA Dihydropyridine derivatives High blood pressure, heart failure, angina 23.7 24.8 21.8 <.01 
M05BA Biphosphonates Prevent bone density loss, treat osteoporosis 20.4 28.2 7.1 <.01 
H03AA Thyroid hormones Hypothyroidism 18.3 23.1 10.0 <.01 
H02AB Glucocorticoids 
Autoimmune and inflammatory disorders, 
cancer, asthma, COPD 
17.0 16.6 17.7 <.01 
N05BA Benzodiazepine derivatives Agitation, anxiety, insomnia, seizures 16.6 19.0 12.4 <.01 
C03CA Sulfonamides, plain  High blood pressure, heart failure 16.5 16.0 17.5 <.01 
C09CA Agents acting on the renin-angiotensin system High blood pressure, heart or kidney disease 16.3 17.7 13.8 <.01 
C03AA Thiazides, plain High blood pressure, heart or kidney disease 15.2 17.0 12.1 <.01 
J01MA Fluoroquinolones Respiratory and urinary tract infections 15.2 15.2 15.1 0.56 
N06AB Selective serotonin reuptake inhibitors Depression 14.7 16.4 11.9 <.01 
A10BA Biguanides Type 2 diabetes 14.3 12.9 16.8 <.01 
J01CA Penicillins with extended spectrum Bacterial infection 13.6 13.6 13.7 0.58 
R03CC Selective beta-2-adrenoreceptor agonists COPD, asthma 13.1 13.3 12.8 <.01 
A06AA Softeners, emollients constipation 12.9 12.8 13.1 0.04 




Figure 2.2 Top 10 Medications Prescribed to Older Adults of Different Age Group Before They Experienced Fall-Related Injuries.  
Note C10AA, HMG CoA reductase inhibitors; A02BC, proton pump inhibitors; C09AA, ACEIs; C07AB, beta blocking agents; 
N02AA, Natural opium alkaloids; C08CA, dihydropyridine derivatives; M05BA, biphosphonates; H03AA, thyroid hormones; 
H02AB, glucocorticoids for systematic use; N05BA, benzodiazepine derivatives
C10AA A02BC C09AA C07AB N02AA C08CA M05BA H03AA H02AB N05BA
66-74 47.3% 30.6% 24.9% 20.0% 24.9% 18.3% 15.5% 14.9% 16.0% 14.2%
75-84 53.4% 36.2% 30.8% 28.2% 26.1% 25.3% 22.5% 18.8% 18.1% 17.6%











Biphosphonates and thyroid hormones were prescribed to 28.3% and 23.1% of females, 
but only to 7.1% and 10.0% males. These two medication classes emerged as the most 
gender specific among the older adults who experienced any fall-related injury. The 
percentage of older adults prescribed these two drug classes also increased with age with 
the age group 85 years and older having the highest percentage (Figure 2.2). 
The central nervous system agents, notably natural opium alkaloids, were prescribed to a 
quarter of female and male older adults. The highest percentage of opioids prescription 
was noted for the age group 75-84 years. Older adults 85 years and older were prescribed 
less opioids than the other two age groups. Benzodiazepine derivatives were prescribed to 
19.0% females and 12.4% males, with an increase with age to 18.5% in the group of 
older adults who were 85 years and older. For antidepressants, such as selective serotonin 
reuptake inhibitors (SSRIs) and other antidepressants (mostly tricyclic antidepressants 
[TCAs]), there was a higher percentage of female users than male users, namely 16.4% 
female, 11.9% male for SSRIs and 13.5% female, 10.7% male for TCAs (Table 2.2).  
Fall-related fractures were diagnosed in 115,230 older adults (40.0% of all older adults 
with any fall-related injury). More women (70.7%) than men (29.3%) experienced fall-
related factures. For 85 years and older age group, the number of females (22,231) was 
almost three times as many as males (7,742). Statins and PPIs were still the top two most 
commonly prescribed medication classes. A higher percentage of males were prescribed 
statins, ACEIs, and BBs than females, while a higher percentage of females were 
prescribed biphosphonates, dihydropyridine derivatives and thyroid hormones. As for age 
differences, adults 85 years and older had the highest percentage of prescribed ACEIs, 
BBs, biphosphonates, dihydropyridine derivatives, thyroid hormones, benzodiazepine 


























C10AA HMG CoA reductase inhibitors 45.4 42.5 52.4 <.01 44.6 50.4 39.6 <.01 
A02BC Proton pump inhibitors 33.1 33.9 31.0 <.01 29.2 35.1 35.4 <.01 
C09AA ACE inhibitors, plain 27.6 25.5 32.8 <.01 23.1 29.5 31.0 <.01 
N02AA Natural opium alkaloids 24.5 24.2 25.2 <.01 23.7 26.0 23.5 <.01 
C07AB Beta blocking agents, selective 24.5 23.7 26.2 <.01 18.4 26.8 29.3 <.01 
M05BA Biphosphonates 23.6 30.0 8.1 <.01 18.9 26.1 26.5 <.01 
C08CA Dihydropyridine derivatives 23.6 24.3 21.8 <.01 17.7 25.2 29.2 <.01 
H03AA Thyroid hormones 18.6 22.3 9.7 <.01 15.1 18.9 22.7 <.01 
N05BA Benzodiazepine derivatives 16.6 18.5 12.1 <.01 13.9 17.8 18.7 <.01 
H02AB Glucocorticoids 16.1 15.5 17.4 <.01 15.3 17.0 15.8 <.01 
C09CA Agents acting on the renin-angiotensin system 15.7 16.7 13.3 <.01 14.1 17.0 16.0 <.01 
C03CA Sulfonamides, plain 15.5 14.9 16.9 <.01 8.3 15.3 25.2 <.01 
C03AA Thiazides, plain 14.7 16.1 11.3 <.01 12.8 15.7 15.7 <.01 
N06AB Selective serotonin reuptake inhibitors 14.6 15.7 11.9 <.01 13.0 14.9 16.4 <.01 
J01MA Fluoroquinolones 14.3 14.2 14.6 0.14 11.6 14.8 17.3 <.01 
J01CA Penicillins with extended spectrum 13.0 13.0 13.1 0.51 13.7 13.3 11.7 <.01 
A10BA Biguanides 12.7 11.7 15.3 <.01 14.1 14.0 9.2 <.01 
R03CC Selective beta-2-adrenoreceptor agonists 12.4 12.3 12.4 0.62 12.6 12.9 11.4 <.01 
A06AA Softeners, emollients 12.2 11.9 13.0 <.01 7.8 13.3 16.5 <.01 
N06AX Other antidepressants  12.1 12.8 10.3 <.01 10.9 12.1 13.5 <.01 
Note a: Wilcoxon rank-sum test; b: Kruskal-Wallis test.  
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C10AA HMG CoA reductase inhibitors 52.0 48.2 57.4 <.01 49.5 57.3 47.3 <.01 
A02BC  Proton pump inhibitors 35.5 37.5 32.5 <.01 31.8 37.3 36.9 <.01 
C09AA ACE inhibitors, plain 30.3 27.3 34.6 <.01 26.1 31.9 32.7 <.01 
C07AB Beta blocking agents, selective 28.7 27.7 30.2 <.01 22.1 30.8 33.2 <.01 
C08CA Dihydropyridine derivatives 25.1 26.5 23.1 <.01 19.3 26.9 29.2 <.01 
N02AA Natural opium alkaloids 24.9 25.4 24.1 <.01 25.0 25.7 23.5 <.01 
M05BA Biphosphonates 19.4 28.1 7.0 <.01 13.9 20.9 23.3 <.01 
H03AA Thyroid hormones 19.1 24.8 11.0 <.01 15.7 19.0 23.1 <.01 
C03CA Sulfonamides, plain 18.1 17.5 19.0 <.01 10.3 17.5 27.6 <.01 
C09CA Agents acting on the renin-angiotensin system 17.4 19.3 14.8 <.01 15.8 19.0 17.0 <.01 
H02AB Glucocorticoids 17.3 17.2 17.5 0.34 16.1 18.3 17.4 <.01 
N05BA Benzodiazepine derivatives 17.2 20.0 13.2 <.01 15.7 17.8 18.0 <.01 
A10BA Biguanides 16.6 15.2 18.6 <.01 18.2 18.1 12.6 <.01 
N06AB Selective serotonin reuptake inhibitors 16.5 18.6 13.6 <.01 15.2 16.9 17.4 <.01 
J01MA Fluoroquinolones 16.1 16.2 16.0 0.64 13.0 16.5 18.9 <.01 
C03AA Thiazides, plain 15.3 17.6 12.1 <.01 13.4 16.7 15.5 <.01 
J01CA Penicillins with extended spectrum 14.4 14.7 14.0 0.06 15.5 14.2 13.7 <.01 
A06AA Softeners, emollients 14.4 14.2 14.6 0.30 10.1 15.2 18.1 <.01 
N06AX Other antidepressants 13.4 14.8 11.5 <.01 13.1 13.0 14.4 <.01 
R03CC Selective beta-2-adrenoreceptor agonists 12.8 13.3 12.0 <.01 13.0 12.9 12.2 0.14 
Note a: Wilcoxon rank-sum test; b: Kruskal-Wallis test
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Fall-related traumatic brain injury was observed in 34,810 older adults (12.1% of all 
older adults with any fall-related injury), 20,246 occurred in females (58.7%) and 14,364 
in males (41.3%). A third (31.7%) of older adults who experienced fall-related traumatic 
brain injury were in the 66-74 age group; with 39.9% and 28.4% in the 75-84 and 85+ 
years old age groups, respectively. Statins and PPIs were the top two most common 
classes of medications. A higher percentage of males diagnosed with fall-related 
traumatic brain injury were prescribed statins and ACEIs than females, while higher 
percentage of females were prescribed biphosphonates and thyroid hormones. As for age 
groups, adults 85 years and older had the highest prescriptions of ACEIs, BBs, 
dihydropyridine derivatives, biphosphonates, thyroid hormones, sulfonamides, 
benzodiazepine derivatives, SSRIs, fluoroquinolones, emollients and other 
antidepressants (Table 2.4). 
2.4 Discussion 
Using health care administrative data, this population study has described the medication 
classes prescribed to older adults in one year prior to a fall-related injury and two specific 
fall-injury types, namely fracture and traumatic brain injury. The results showed that 
among older adults sustaining any fall-related injury, 48.5% were prescribed statins, 
34.3% PPIs, 25.0% opioids, and16.6% anxiolytics. Similar patterns of medication 
prescription were also found for fall-related fractures and traumatic brain injury. Notably, 
36.4% of older adults were prescribed 5-9 different medication classes and 41.2% were 
prescribed 10 or more medication classes within one year prior to fall-related injuries.  
The findings of this study indicated that medications prescribed to older adults who had 
any fall-related injury were similar, but not the same to medications prescribed to the 
general population of older adults in Ontario (CIHI, 2018b). CIHI reported that, in the 
whole year of 2016, there were 51.7% and 17.3% of Ontario general population of older 
adults (OGP-OAs) who were prescribed statins and agents acting on RAS (CIHI, 2018b), 
while in our study, 48.5% and 16.3% of older adults who had fall related injury (FRI-
OAs) were prescribed statins and agents acting on RAS within the year before the injury. 
However, compared to prescription in OGP-OAs, higher percentage of FRI-OAs were 
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prescribed with ACEIs, BBs, opioids, biphosphonates, benzodiazepine derivatives, 
thiazides, and SSRI. For example, CIHI reported there were 15.4% of OGP-OAs 
prescribed opioids, while in our study, 25.0% of FRI-OAs were prescribed opioids the 
year before their fall-related injury. The percentage of being prescribed SSRI in FRI-OAs 
and OGP-OAs were 14.6% and 10.5% respectively, biphosphonates were 20.4% and 
9.4% respectively, benzodiazepine derivatives were 15.2% and 10.8% respectively.  
The above comparison confirmed that all medication classes (except biphosphonates) 
with a higher percentage of prescription in older adults who had any fall-related injury 
were recognized as FRIDs. These classes of medications have been repeatedly identified 
to be related to falls and fall-related injury (Lee & Holbrook, 2017; Machado-Duque et 
al., 2018; Richardson et al., 2015; Seppala, Wermelink, et al., 2018).  Most studies 
currently identify anti-hypertensive agents, antidepressants, antiepileptics, analgesics, 
sedatives and hypnotics, anti-Parkinsonian drugs, antipsychotics, and anxiolytics as 
FRIDs. In this aspect, our findings support previous studies on FRIDs and their 
association with falls and fall-related injury.  
In this study, however, a number of other medication classes such as statins (48.5%), 
PPIs (34.3%), biphosphonates (20.4%), thyroid hormones (18.3%), glucocorticoids 
(17.0%), and fluoroquinolones (15.2%) were prescribed to a high percentage of older 
adults. Unfortunately, research regarding the association between these medication 
classes and fall-related injuries has not been well established (de Vries et al., 2018; 
Seppala, van de Glind, et al., 2018). The link between these commonly prescribed 
medication classes and fall-related injury in older adults needs to be further explored.  
Of all fall-related injury types, fractures are the most common (PHAC, 2014). Findings in 
this study showed that medications prescribed prior to fall-related fractures were similar 
to medication prescribed prior to any fall-related injury. Hip fractures were extensively 
used in research as fall-related outcome because they were almost always caused by falls 
and were hospitalized, minimizing the number of missing cases (Hayes et al., 1996; 
Manchado-Duque et al., 2018, Payne et al., 2013, Thaler et al., 2016). A number of 
studies reported different percentages of older adults using certain medications prior to 
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hip fractures because their lookback windows were dissimilar. For example, Wang et al. 
(2000) reported 2.2% of older adults were prescribed statins within 180 days prior to hip 
fractures, while Rejnmark et al. (2004) reported that 66% of Danish older adults used 
statins within five years prior to hip fracture. A Swedish population-based study reported 
53% of older adults who were 75 years and older used diuretics, 43% BBs, 18% CCBs, 
30% agents acting on RAS, 33% opioids, 25% anxiolytics, 37% hypnotics and sedatives 
and 29% antidepressants within one year prior to a hip fracture (Thorell et al., 2014). 
Percentage of older adults prescribed antihypertensive medications and psychotropic 
medications in Thorell’s study (2014) were much higher than ours. Possible explanation 
could be that their participants were older and their only outcome was hip fractures. 
Fall-related TBIs in older adults are gaining increasing recognition in recent studies 
(Kannus et al., 2007; Hartholt et al., 2011). Currently only anticoagulants and antiplatelet 
agents were reported to be associated with TBIs due to an increased risk of intracranial 
bleeding (Boltz et al., 2015; Qiu et al., 2019). However, our finding indicated that higher 
percentage of statins, PPIs, ACEIs, BBs, sulfonamides, SSRIs and biguanides were 
prescribed prior to fall-related TBIs than fall-related fractures, which offers a good 
starting point for further exploration of the association between these medications and 
fall-related TBIs.   
Medications can be seen as a surrogate for a person’s health status and the number of 
medications a valid proxy for multi-comorbidities (Schneeweiss et al., 2001). Using 
multiple medications concurrently is common in older adults with multi-comorbidities 
and is associated with adverse outcomes such as mortality, falls, injuries, adverse drug 
reactions, and prolonged length of stay in hospital (Caughey et al., 2010; Correa-Pérez et 
al., 2017; Milton et al., 2008). The risk of having adverse consequences and experiencing 
harm increased with each additional medication because of complicated drug-drug and 
drug-disease interactions (Maher et al., 2014). Our study showed that 77.6% of older 
adults who had any fall-related injury were prescribed five or more different classes of 
medication within one year before the injury and 41.2% were prescribed ten or more 
different classes of medication. CIHI reported that 65.7% general population of older 
adults in Canada were prescribed five or more medication classes and 26.5% were 
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prescribed ten or more medication classes in the year of 2016 (CIHI, 2018b). Compared 
with the general population of older adults, a higher percentage of older adults who 
experienced fall-related injuries were prescribed multiple medication classes before the 
injury. Untangling multiple medications prescribed to older adults by enhancing 
communication between patients and healthcare providers, improving cooperation of 
pharmacists, family doctors, and specialists in prescribing practices will be important in 
future research. 
2.4.1 Strengths and Limitations 
The strengths of this study are the large number of observations and provincial 
representativeness. This study included data for over a quarter million older adults and 
provided detailed information on demographics, comorbidities and strictly defined fall-
related injury using ICD-10-CA codes. All the data were obtained from IC/ES databases 
which were reported to have excellent data completeness (Levy et al., 2003) and high 
quality as in previous studies (Aiken et al., 2016; Liu et al., 2018; Macri et al., 2017). 
Several limitations are associated with this study. First is the inherent limitation of 
administrative data that may lead to underreporting of some diagnoses (Sarrazin & 
Rosenthal, 2012), which might have been omitted during the coding process. Second, 
only dispensed drugs were recorded in the ODB database and the information collected 
through the ODB database could be an underestimation of prescriptions. Additionally, 
prescription (and even dispensing) cannot be equated with actual use, therefore the 
registry data could be an overestimation of drug use in our population of older adults.  
This study laid the foundation for the consecutive studies in this program of research. 
With the knowledge of medication classes being prescribed to older adults prior to a fall-
related injury, a comparison of medication classes prescription patterns between older 
adults who had a fall-related injury and older adults without a fall-related injury is now 
possible, which is essential in the upcoming case-control studies examining the 
association between medication and fall-related injuries. Future research could also 
include examine the association between medication prescribed to older adults and 
different types of fall-related injuries and evaluate the effectiveness of interventions 
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aimed at improving the appropriateness of prescribing in older adults to reduce the 
occurrence of fall-related injury. 
2.5 Conclusion 
This study described the medications classes and numbers of medication classes 
prescribed to older adults prior to a fall-related injury. Gender difference in medication 
prescribed was noted, specifically more females were prescribed antidepressants and 
anxiolytics. A higher percentage of people 85 years and older were prescribed 
antihypertensive agents, anxiolytics and antidepressants. There were 77.6% of older 
adults who were prescribed five or more different medication classes prior to any fall-
related injury. Well-designed cohort studies are needed to determine the association 
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Chapter 3  
3 Association between Fall-related Injury and Medication 
Prescribed to Older Adults within One Month Prior to the Injury 
3.1 Introduction 
Roughly 30% of older adults aged 65 years or older fall every year (Chang et al., 2010; 
Tinetti et al., 2006). Falls are the leading cause of non-fatal injuries and death among 
older adults in many countries and regions (Bergen et al., 2016; Ellingsen et al., 2018; 
National Council of Aging, 2018; Public Health Agency of Canada, 2014). Not all falls 
result in injuries, some minor injuries that may or may not require medical treatment or 
consultation, occur in 30-50% of falls, while 5-10% of falls lead to serious injuries such 
as fractures, dislocation of joints, or brain injury (Cameron et al., 2012; Gillespie et al., 
2012; Goldacre et al., 2002; Health Quality Ontario, 2008). Although there is no 
consensus on the definition of fall-related injury, most studies refer to it as “an injury 
requiring emergency or inpatient treatment” (Schwenk et al., 2012).  Fall-related injuries 
can result in adverse consequences both to individuals and to the public health care 
system (Burns et al., 2016; Gill et al., 2013, Scott et al., 2010). Disability resulting from 
falls increased by 54% in United States between 1990 and 2010 (Murray et al., 2013). In 
2010, injurious falls in older adults in Canada resulted in over $3.3 billion in direct costs 
to the public health care system (Parachute, 2015). The total cost of fall-related injury in 
U.S was $50 billion in 2015 (National Council of Aging, 2018). Subsequently, it has 
become increasingly recognized that fall-related injury is a growing public health 
concern, especially with an increasing aging demographic (He et al., 2016).  
The risk factors for fall-related injuries in older adults are multifactorial. History of 
previous falls, age, mobility and balance problems, and certain medication classes were 
reported to be associated with fall-related injuries (Gillespie et al., 2012; Mccoy, et al., 
2017; Nilsson et al., 2016). Many studies demonstrated that use of certain medications 
and concurrent use of more than four medications enhanced the risk of falls and fall-
related injury in older adults (Ambrose et al., 2013; Huang, et al., 2012; Pan et al., 2014; 
Hart et al., 2019). A recent systematic review reported that loop diuretics enhanced the 
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risk of falls by 36%, and antipsychotics, analgesics such as opioids, antidepressants and 
benzodiazepines were associated with increasing the risk for injurious falls by 60-80% in 
older adults (Seppala, Wermelink, et al., 2018). Polypharmacy was also identified as 
being associated with an increased risk of fall-related injuries and fractures (Iihara et al., 
2016; Pan et al., 2014). 
However, previous studies have focused mainly on fall-risk increasing drugs (FRIDs) 
such as anti-hypertensives and drugs acting on the nervous system. Currently lacking in 
the research literature are studies examining the association between medications 
currently not listed on the established FRID list (the Swedish National Board on Health 
and Welfare, 2010) and fall-related injury in older adults. Furthermore, there is a lack of 
robust evidence related to whether exposure to statins, proton pump inhibitors (PPIs), 
antiplatelets, glucose-lowering medications, laxatives, and anticholinergic drugs are 
associated with fall-related injury (Seppala, van de Glind, et al., 2018). This is important 
as these are considered commonly prescribed medications. For example, Canadian 
Institute for Health Information ([CIHI], 2018a) reported that these types of medication 
have been prescribed to 30-50% of older adults in the province of Ontario, Canada. 
Therefore, it is necessary to expand inquiry beyond FRIDs to include more medication 
classes and explore their association with fall-related injury.  The purpose of this study 
was to evaluate the association between fall-related injuries and medication classes 
prescribed to older adults within 30 days prior to the injury.  
3.2 Methods 
3.2.1 Study Design  
We conducted a population-based, case-control study using administrative secondary 
health care data for Canada’s most populous province of Ontario. Ontario is the largest 
province in Canada, with a population of 14.7 million and 2.6 million older adults over 
the age of 65 (Statistics Canada, 2020), all of whom have access to universal healthcare 
services. The extraction of eligible participants in this study was conducted by IC/ES 
analysts, based on a carefully prepared data creation plan (DCP, Appendix B). IC/ES is 
an independent, non-profit research institute whose legal status under Ontario’s health 
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information privacy law allows it to collect and analyze health care and demographic 
data. IC/ES is a prescribed entity under the section 45 of Ontario’s Personal Health 
Information Protection Act. Section 45 authorizes IC/ES to collect personal health 
information, without consent, for the purpose of analysis or compiling statistical 
information with respect to the management of, evaluation or monitoring of, the 
allocation of resources to or planning for all or part of the health system. Projects 
conducted under section 45, by definition, do not require review by a Research Ethics 
Board. This project was conducted under section 45, and was approved by IC/ES’ 
Privacy and Legal Office. However, ethics approval for this series of studies was required 
in Western University, and it was obtained from the Research Ethics Board at Western 
University, London, Ontario, Canada (HSREB #109335, detailed information was 
provided in Appendix C).  
3.2.2 Data Sources 
We used records from three databases held by IC/ES: (1) the Ontario Drug Benefit 
(ODB) database, which provides prescription drug coverage data for residents over the 
age of 65, including individuals in long-term care homes (Government of Ontario, 2019); 
(2) the National Ambulatory Care Reporting System (NACRS), which captures 
information on visits to emergency departments (EDs) and community-based ambulatory 
care facilities; and (3) the Ontario Registered Persons Database (RPDB), which contains 
demographic information for Ontario residents. These datasets were linked using unique 
encoded identifiers and analyzed at IC/ES, which ensured the confidentiality of personal 
and health information.  
Diagnoses were extracted from NACRS database and medication prescribed within 30 
days was drawn from the ODB database. Age, sex, residence area (i.e., Local Health 
Integration Networks [LHINs]), and neighborhood income quintile were extracted from 
RPDB dataset. LHINs are the 14 health authorities that are responsible for the regional 
public healthcare service in Ontario (LHINs, 2020). Neighborhood income quintile is a 
measure of socioeconomic status that divides the population living in same dissemination 
area into 5 income groups (1 represents the lowest income; 5 represents the highest 
income) with approximately 20% of the population in each group (CIHI, 2016).  
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3.2.3 Selection of Cases and Controls 
The cases in this case-control study had to fulfill the following criteria: (a) residing in 
Ontario; (b) 66 years and older, (c) visited ED for fall-related injury between January 1, 
2010 and December 31, 2014. The ODB program covers the cost of prescription 
medications for all Ontarians 65 years and older, therefore those under the age of 66 were 
excluded to avoid incomplete medication information in their first year of eligibility. 
Patients who visited an ED for fall-related injury were captured by the NACRS database. 
The ICD-10-CA codes (CIHI, 2018b; World Health Organization [WHO], 2020) were 
used to confirm patients’ diagnosis. Fall-related injury in this study was defined by 
combining the ICD-10-CA codes for falls W00-W19, and codes for injury S00-S99 or 
T00-T14 (Appendix D). The date when the patient was admitted to the ED due to a fall-
related injury was defined as the index date. For individuals who have had multiple 
entries to EDs, only the information of first entry was used. Cases were excluded if they 
had experienced an in-hospital fall-related injury, were transferred from another ED, left 
the ED without being registered, had a scheduled ED visit or died in ED. Controls were 
older adults without a fall-related injury diagnosis extracted from Ontario RPDB, and 
matched to cases by the same age, sex, and LHIN, with no fixed ratio. An index date was 
assigned randomly to each control within the five-year study period. As the authors had 
no access to the database hosted by IC/ES, all of the above operations were completed by 
an IC/ES analyst according to a pre-agreed DCP (Appendix B) to generate the matched 
dataset, which was then provided to the research team. 
3.2.4 Medication Use   
Use of a certain medication class within 30 days prior to a fall-related injury was 
regarded as one of the risk factors for fall-related injury. Medications prescribed to case 
and control groups were extracted from ODB datasets. ODB datasets uses Drug 
Identification Numbers (DIN) assigned by Health Canada (Health Canada, 2018) to 
identify different medications. Each DIN included information on medication’s 
manufacturer, trade name, active ingredients, strength of the active ingredients, 
pharmaceutical form, and route of administration (Health Canada, 2018). In order to 
better understand and compare findings of this study with the results of other studies, 
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DIN codes were converted to Anatomical Therapeutic Chemical (ATC) level 5 codes and 
grouped into 4th level codes. In ATC classification system, each medication is classified 
in a hierarchy with five levels (WHO, 2019). The 1st level includes fourteen anatomical 
main groups. These main groups are divided into 2nd level which is the pharmacological 
or therapeutic group. The 3rd and 4th levels are chemical, pharmacological or therapeutic 
subgroups and the 5th level is the chemical substance. ATC 4th level is the level used to 
count number of different medications because it is the level which aggregates 
medications just above their descriptive chemical substance (Krause, 2008).The numbers 
of older adults who were prescribed with each ATC 4th level medication class in both the 
case and control groups were calculated and the analysis of the association between each 
medication class and fall-related injury was conducted.  
3.2.5 Statistical Analysis 
The difference between case and control groups characteristics such as age, sex, income 
quintile, residence area (LHINs), and the number of medication classes prescribed were 
evaluated by Wilcoxon rank sum test, with a significance level of .01. Due to multiple 
testing, a conservative Bonferroni adjustment for p-value of each individual test was 
applied. If the adjusted p-value >1, we define it as 1.00. Older adults were categorized 
into three age groups, aged 66-74, 75-84, and 85+.  The number of medication classes 
prescribed to each older adult within 30 days of the fall-related injury was calculated and 
classified into one of four categories: 0-4, 5-9, 10-14, and 15 or more different 
medication classes (CIHI, 2018a). An examination of the extracted data revealed that 
there were significant differences between the case and control groups on matched factors 
such as age, sex and LHINs, so the matching seemed to be incomplete. To address the 
potential for residual confounding, these factors were included in the adjusted 
multivariable model. Univariate logistic regression was used to calculate the unadjusted 
Odds Ratios (ORs) and 99% confidence intervals (CIs) for medication classes. 
Medication classes for topical use (ATC ‘D’ codes) and treatment of cancer (ATC ‘L’ 
codes) were excluded. Multivariate logistic regression model was conducted for each 
medication class, adjusted for sex, age group, residence area (LHINs), neighborhood 
income quintile, and number of medication classes prescribed. The corresponding ORs 
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were recorded as adjusted ORs (aORs). Attributable risk among the exposed group (older 
adults who were prescribed with each medication class) and population attributable risk 
were calculated for each medication class. All the analysis was conducted with SAS 9.4 
(SAS Institute, 2013). 
3.3 Results 
This study included 1,005,066 community-dwelling older adults. The case group 
included 255,270 older adults who experienced a fall-related injury over the five-year 
period. The mean age of the cases was 77.7±7.7 years and 61.1% were female. The 
control group included 749,796 older adults, with a mean age of 75.1±7.5 years old and 
54.0% female. The case and control groups were similar in income quintile distribution 
but were significantly different in LHINs, age group constitution, female percentage, and 





Table 3.1 Characteristics of Case and Control Group 
Characteristics 
Case 
(n = 255,270) 
Control 





Age Mean±SD 77.7±7.7 75.1±7.5   
Age group 66-74 (N, %) 100,027 (39.2) 405,172 (54.0) <.01 Reference 
Age group75-84 (N, %) 96,874 (37.9) 235,486 (31.4) <.01 1.57 [1.55, 1.59] 
Age group 85+ (N, %) 58,396 (22.9) 109,138 (14.6) <.01 1.85 [1.82, 1.88] 
Female (N, %) 157,957 (61.1) 415,513 (54.6) <.01 1.30 [1.29, 1.32] 
Local Health Integration Networks, LHINs (N, %)     
   LHIN 01 Erie St. Claire 13,652 (5.3) 39,302 (5.2) .23 1.21 [1.16, 1.25] 
   LHIN 02 South West 21,286 (8.3) 54,948 (7.3) <.01 1.42 [1.37, 1.47] 
   LHIN 03 Waterloo Wellington 12,654 (5.0) 37,835 (5.0) .30 1.21 [1.16, 1.26] 
   LHIN 04 Hamilton Niagarac 32,006 (12.5) 87,984 (11.7) <.01 1.28 [1.23, 1.32] 
   LHIN 05 Central West 10,915 (4.3) 38,676 (5.2) <.01 Reference 
   LHIN 06 Mississauga Halton 17,264 (6.8) 56,762 (7.6) <.01 1.08 [1.05, 1.12] 
   LHIN 07 Toronto Central 20,608 (8.1) 63,701 (8.5) <.01 1.12 [1.08, 1.16] 
   LHIN 08 Central 29,636 (11.6) 95,770 (12.8) <.01 1.09 [1.05, 1.12] 
   LHIN 09 Central East 30,768 (12.1) 92,220 (12.3) <.01 1.19 [1.15, 1.23] 
   LHIN 10 South East 13,040 (5.1) 34,213 (4.6) <.01 1.41 [1.36, 1.47] 
   LHIN 11 Champlain 24,762 (9.7) 72,939 (9.7) 1.00 1.21 [1.17, 1.25] 
   LHIN 12 North Simcoe Muskoka 9,797 (3.8) 26,681 (3.6) <.01 1.35 [1.29, 1.41] 
   LHIN 13 North East 13,621 (5.3) 35,414 (4.7) <.01 1.38 [1.33, 1.49] 
   LHIN 14 North West 5,261 (2.1) 13,351 (1.8) <.01 1.42 [1.33, 1.49] 
Neighborhood Income Quintile (N, %)d    
  1 52,413 (20.5) 150,600 (20.1) <.01 0.94 [0.92, 0.96] 
  2 53,161 (20.8) 156,131 (20.8) 1.00 0.97 [0.95, 0.99] 
  3 50,081 (19.6) 146,952 (19.6) 1.00 0.98 [0.96, 1.00] 
  4 49,793 (19.5) 144,927 (19.3) .26 1.01 [0.99, 1.03] 
  5 (highest income) 49,822 (19.5) 151,186 (20.2) <.01 Reference 
Number of Medication Classes (N, %)     
  0-4 179,175 (70.2) 635,056 (84.7) <.01 Reference 
  5-9 55,233 (21.6) 90,111 (12.0) <.01 1.95 [1.92, 1.98] 
  10-14 17,194 (6.7) 21,036 (2.8) <.01 2.50 [2.43, 2.57] 
  15+ 3,667 (1.4) 3,593 (0.5) <.01 3.23 [3.04, 3.44] 
Note. a Bonferroni-adjusted p value;  
 badjusted ORs were obtained by putting age group, sex, LHINs, income quintile and 
number of medications into a multivariate regression model.  
c LHIN4: Hamilton Niagara Haldimand Brant;  
d Neighborhood income quintile is a measure of socioeconomic status that divides the 
population living in same dissemination area into 5 income groups (1 represents the 
lowest income; 5 represents the highest income) with approximately 20% of the 




One hundred and fifty medication classes entered the univariate and multivariate 
regression model. Given the numerous study covariates, only association between fall-
related injury and ATC 4th medication classes with an aOR>1.20 and more than 10,000 
older adult users were presented in Table 3.2. Proton pump inhibitors (PPIs, A02BC), 
statins (C10AA), pennicillins with extended spectrum (J01CA) and biphosphonates 
(M05BA) were associated with increasing the odds of fall-related injury by 20-30%. 
Drugs for constipation (A06AA, A06AB), testosterones (G04CB), anticholinesterases 
(N06DA), and drugs for asthma (R03CC) were associated with increasing the odds of 
fall-related injury by over 50%. Older adults prescribed with non-steroid anti-
inflammatory drugs (NSAIDs) such as propionic acid derivatives (M01AE), anti-
epileptics (N03AX) were over two times more likely to experience fall-related injury than 
non-users (M01AE: aOR=2.36, 99%CI [2.24-2.49]; N03AX: aOR=2.02, 99%CI [1.92-
2.13]). Using opioids (N02AA) increased the likelihood of having a fall-related injury by 
3.5 times (aOR=3.55, 99%CI [3.48-3.62]). 
The attributable risk (AR) percentages among exposed group and population attributable 
risk (PAR) percentages were shown in Table 3.3. Low PARs indicate that either the risk 
of experiencing fall-related injury is low, or that prescription of particular medication is 
not prevalent (or both). Avoiding prescribing these medications will have little effect in 
preventing fall-related injuries. A high PAR indicates that avoiding prescribing these 
medications could be effective in preventing fall-related injuries. For example, 76.87% of 
older adults who were prescribed natural opium alkaloids experienced fall-related injuries 
and 13.04% of all cases of fall-related injuries could be prevented if no natural opium 
alkaloids were prescribed. The findings of Study 1 indicate that avoiding prescriptions of 
proton pump inhibitors, emollients, contact laxatives, platelet aggregation inhibitors, 
statins, biphosphonates, SSRIs, TCAs, anticholinesterases and selective beta-2-
adrenoreceptor agonists could have considerable impacts on reducing the fall-related 
injuries in older adults.
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Table 3.2 Association between Different Medication Classes and Fall-related Injury in Older Adults 
ATC 
codes 





A02BC Proton pump inhibitors for gastric ulcer and GERD 1.97 [1.93, 2.00] 1.21 [1.19, 1.24] 
A06AA Softeners, emollients for constipation 2.90 [2.81, 2.99] 1.70 [1.64, 1.75] 
A06AB Contact laxatives for constipation 2.69 [2.59, 2.79] 1.58 [1.52, 1.64] 
B01AC Platelet aggregation inhibitors excl. heparin prevent thrombosis 2.19 [2.12, 2.27] 1.31 [1.27, 1.36] 
C10AA HMG CoA reductase inhibitors lower lipids 1.72 [1.70, 1.75] 1.25 [1.23, 1.27] 
C10AZ Other lipid modifying agents lower lipids 1.75 [1.67, 1.83] 1.32 [1.25, 1.38] 
G04BD Drugs for urinary frequency and incontinence for incontinence 2.28 [2.17, 2.40] 1.34 [1.27, 1.41] 
G04CA Alpha-adrenoreceptor antagonists for benign prostatic hyperplasia 1.78 [1.72, 1.84] 1.36 [1.32, 1.41] 
G04CB Testosterone-5-alpha reductase inhibitors for benign prostatic hyperplasia 1.97 [1.88, 2.07] 1.58 [1.50, 1.66] 
J01CA Penicillins with extended spectrum for bacterial infection 1.50 [1.43, 1.57] 1.27 [1.21, 1.34] 
M01AB Acetic acid and related substances anti-inflammation 1.64 [1.56, 1.73] 1.36 [1.29, 1.44] 
M01AE Propionic acid derivatives anti-inflammation 2.68 [2.55, 2.83] 2.36 [2.24, 2.49] 
M01AH Coxibs anti-inflammation 1.91 [1.82, 2.02] 1.40 [1.32, 1.48] 
M05BA Biphosphonates preventing osteoporosis 1.93 [1.89, 1.98] 1.30 [1.27, 1.33] 
N02AA Natural opium alkaloids for moderate to severe pain 4.32 [4.24, 4.41] 3.55 [3.48, 3.62] 
N03AX Other antiepileptics for epilepsy 3.07 [2.92, 3.23] 2.02 [1.92, 2.13] 
N05AH Diazepines, oxazepines, thiazepines and oxepines for schizophrenia 2.34 [2.25, 2.44] 1.28 [1.23, 1.34] 
N06AA Non-selective monoamine reuptake inhibitors for anxiety, tension and depression 1.91 [1.82, 2.00] 1.25 [1.19, 1.31] 
N06AB Selective serotonin reuptake inhibitors for anxiety, tension and depression 2.98 [2.91, 3.06] 1.84 [1.79, 1.90] 
N06AX Other antidepressants for anxiety, tension and depression 2.59 [2.52, 2.66] 1.54 [1.49, 1.58] 
N06DA Anticholinesterases for Alzheimer's and myasthenia gravis 2.82 [2.74, 2.91] 1.53 [1.48, 1.58] 
R03CC Selective beta-2-adrenoreceptor agonists for asthma/COPD 2.30 [2.22, 2.39] 1.57 [1.51, 1.63] 
Note. *OR adjusted for sex, age group, LHINs, income quintiles, and number of medication classes prescribed;  
GERD: gastro-esophageal reflux disease. BPH: benign prostatic hyperplasia. COPD: chronic obstructive pulmonary disease
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Table 3.3 Attributable Risk Percentage of Exposed Group and Population Attributable 
Risk (PAR) for Each Medication Class 
ATC 
codes 
Drug name ARe (99%CI)* 
PAR 
(%) 
A02BC Proton pump inhibitors 49.12 [48.22-50.01] 7.66 
A06AA Softeners, emollients 65.48 [64.43-66.50] 3.86 
A06AB Contact laxatives 62.84 [61.45-64.18] 2.38 
B01AC Platelet aggregation inhibitors excl. heparin 54.34 [52.78-55.84] 2.25 
C10AA HMG CoA reductase inhibitors 41.92 [41.04-42.79] 9.09 
C10AX other lipid modifying agents 42.70 [39.91-45.37] 0.79 
G04BD Drugs for urinary frequency and incontinence 56.05 [53.77-58.22] 1.03 
G04CA Alpha-adrenoreceptor antagonists 43.75 [41.91-45.54] 1.81 
G04CB Testosterone-5-alpha reductase inhibitors 49.30 [46.80-51.69] 0.94 
J01CA Penicillins with extended spectrum 33.23 [29.91-36.40] 0.56 
M01AB Acetic acid and related substances 39.09 [35.76-42.24] 0.57 
M01AE Propionic acid derivatives 62.73 [60.73-64.62] 1.17 
M01AH Coxibs 47.73 [44.90-50.41] 0.75 
M05BA Biphosphates 48.26 [47.02-49.47] 3.94 
N02AA Natural opium alkaloids 76.87 [76.40-77.32] 13.04 
N03AX Other antiepileptics 67.40 [65.68-69.03] 1.38 
N05AH Diazepines, oxazepines, thiazepines and oxepines 57.30 [55.59-58.94] 1.78 
N06AA Non-selective monoamine reuptake inhibitors 47.56 [45.02-49.98] 0.93 
N06AB Selective serotonin reuptake inhibitors 66.45 [65.57-67.31] 5.33 
N06AX Other antidepressants 61.31 [60.23-62.35] 4.14 
N06DA Anticholinesterases 64.59 [63.45-65.70] 3.36 
R03CC Selective beta-2-adrenoreceptor agonists 56.51 [54.87-58.09] 1.97 
Note *ARe=Attributable Risk Percentage among exposed group (Exposed refers to older 





This population-based, case control study examined the association between fall-related 
injury and medication classes prescribed to older adults within 30 days prior to the injury. 
The result of our study provided novel findings on several mediation classes that were 
associated with increased odds of fall-related injury in older adults, such as medication 
classes used for benign prostatic hyperplasia, bacterial infections and bronchodilators.  
Previous studies have reported a positive association between fall-related injury in older 
adults and drugs acting on the central nervous system (CNS) such as opioids (N02A) 
(Söderberg et al., 2013), antiepileptics (N03) (Resnick et al., 2012; Sylvestre et al., 2012), 
anti-Parkinson agents (N04) (Resnick et al., 2012), antipsychotics (N05A) (Byers, et al., 
2008; Resnick et al., 2012), antidepressants (N06A) (Kerse et al., 2008; Sterke et al., 
2012), and anticholinesterases (N06DA) (Richardson et al., 2015; Salahudeen et al., 
2015). Findings from our study were consistent with these studies, but unique to our 
study is that all of our assessments on different medication classes came from the same 
population, while other studies had various target populations (Kerse et al., 2008; 
Resnick et al., 2012; Sylvestre et al., 2012); or were focused on one or two specific 
medication classes (Kerse et al., 2008; Söderberg et al., 2013). The explanations why 
these medication classes were associated with falls and fall-related injuries focused on 
side effects such as confusion, blurred vision, dizziness, sedation, postural hypotension, 
and extra-pyramidal effects (Daoust et al., 2018; Hill & Wee, 2012; Joe & Forester, 2010; 
Masud et al., 2013; Quach et al., 2013).  
Kelly et al. (2003) and Kuschel et al (2015) used population-based, administrative data to 
identify a wide range of medication classes that were associated with fall-related injury in 
older adults (Kelly et al., 2003; Kuschel et al., 2015). Both studies captured medication 
prescription within 30 days prior to the fall-related injury in older adults. Kelly et al. 
(2003) used health registry data from Alberta, Canada in 1997/1998 fiscal year. They 
found that narcotic pain killers, anti-convulsants (anti-epileptics), and anti-depressants 
were independently associated with an increased risk of sustaining injurious falls. The 
authors tried to eliminate the influence of comorbidities by using various comorbidities as 
confounding factors. However, this is complicated because multiple medication classes 
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could be used in the treatment of one comorbidity while one medication class could be 
used to treat multiple comorbidities. The real effect of each single medication class on 
injurious falls is difficult to fully define. Kuschel and colleagues (2015) reported twenty 
most commonly prescribed ATC 3rd medication classes and their association with fall-
related injuries using Swedish public health data. Additional to CNS drugs (N02A, 
N02B, N05C and N06A), drugs for peptic ulcer (A02B), constipation drugs (A06A), 
antithrombotic agents (B01A), Vitamin B12 (B03B), Calcium (A12A), and NSAIDs 
(M01A) were reported to be independently associated with fall injuries. Consistent with 
Kuschel et al., our study found a positive association between PPIs (A02BC), 
constipation drugs (A06AA, A06AB), anti-thrombotic agents (B01AC, B01AE), and 
NSAIDs (M01AB, M01AE, and M01AH) and fall-related injury. What is new in our 
findings, is positive association of lipid-lowering agents (statins, C10AA), drugs for 
benign prostatic hyperplasia (G04CA and G04CB), pennicillins with extended spectrum 
(J01DB), biphosphonates (M05BA), and selective 𝛽-2-adrenoreceptor agonists for 
asthma (R03CC) with fall-related injuries in older adults.  
A recent systematic review by de Vries et al. (2018) reported that statins had a protective 
effect on fall-related injury in older adults. Contrary to this, our study identified that 
statins were associated with increased odds of fall-related injuries (aOR= 1.25, 99%CI 
[1.23-1.27]). Other studies have described that the side effects of statins, such as 
myopathy and muscle weakness, were more prevalent and serious in elderly patients than 
younger patients (Horodinschi et al., 2019; Mansi et al., 2013). Muscle disorders 
associated with statins contribution to older adults’ physical deconditioning and frailty 
(Curfman, 2017) could in part explain increased risk for fall-related injury. According to 
the CIHI 2018 report, statins were prescribed to nearly half of Canadian older adults, but 
percentage of statins users decreased with age (CIHI, 2018a). Future studies are needed 
to explore the impact of statins on fall-related injury in different age groups of older 
adults. They will provide clinicians with more confidence in balancing the risk and 
benefit in prescribing statins to older adults. 
The finding that 𝛼 -adrenoreceptor antagonists (G04CA) and testerones-5 𝛼 reductase 
inhibitors (G04CB) might increase the odds of fall-related injury in older adults by 36-
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58% was rather new. The 𝛼-adrenoreceptor antagonists are used for the treatment of 
hypertension, so it is plausible that known side effects of 𝛼-adrenoreceptor antagonists, 
such as orthostatic hypotension, dizziness, drowsiness and fatigue could lead to fall-
related injuries (Sica, 2005). Testerones-5 𝛼 reductase inhibitors have some 
cardiovascular side effects, such as syncope and hypotension that could also lead to falls 
and serious fall-related consequences (Lee & Cho, 2018). Welk et al. (2015) did not find 
that using 5 𝛼 reductase inhibitors was related to fractures (OR = 0.88, 95% CI [0.70-
1.10]), but they explained that physicians prescribed 5 𝛼 reductase inhibitors only to 
older adults that were judged to have low risk of falls or fractures. 
Our study also found several anti-bacterial infection agents were associated with 
increased odds of fall-related injury. For example, first-generation cephalosporins 
(J01DB) were associated with increasing the odds of fall-related injury by 2.8 times 
(aOR=2.79, 99%CI [2.64-2.96]). Users of penicillins with extended spectrum (J01CA) 
were 27% more likely to have a fall-related injury than non-users (aOR=1.27, 99%CI 
[1.21-1.34]). The findings that some NSAIDs were also positively associated with fall-
related injury indicated that infection itself could have an impact in the occurrence of fall-
related injury. Future research that will take infection into consideration as a confounding 
factor might better demonstrate the association between anti-inflammatory and anti-
infective agents and fall-related injury in older adults.  
It was not expected to see biphosphonates (M05BA), commonly used to treat 
osteoporosis, on the list of medications that were associated with increased odds for fall-
related injury (aOR=1.30, 99%CI [1.27-1.33]). This was contrary to Caffarelli et al. 
(2017) who found that biphosphonates offer a null or protective effect on falls in older 
adults. A possible explanation for this contradictory finding may be that individuals 
taking biphosphonates for osteoporosis are more suspectable to fall-related injuries due to 
the nature of the medical condition (Kärkkäinen et al., 2010; Uusi-Rasi et al., 2013). We 
were unable to tease apart the role of osteoporosis diagnosis in our analysis.  
Selective 𝛽-2-adrenoreceptor agonists, also known as bronchodilators, are used as 
mainstay treatment for respiratory diseases, such as bronchial asthma and COPD.  Mayo 
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and colleagues (1989) reported bronchodilators were not associated with increased odds 
of falls in hospitals among older adults, but studies examining the association between 
bronchodilators and fall-related injury were scarce. In our study, selective 𝛽-2-
adrenoreceptor agonists were independently associated with fall-related injury 
(aOR=1.43, 95% CI [1.39 - 1.47]). The CIHI reported that selective 𝛽-2-adrenoreceptor 
agonists were prescribed to 13.1% Ontario older adults in 2016 (CIHI, 2018a), which 
makes them a common medication class prescribed to older adults, and continued 
investigation into their relation to fall-related injury is necessary.  
We noticed that income level (neighborhood income quintile) was not associated with 
fall-related injuries in older adults, after adjustments for sex, age group, residence area 
(LHINs) and number of medication classes prescribed. Previously, socioeconomic status 
was reported to be associated with higher risk of falls and worse outcomes after injuries 
(Cruz et al., 2012; Gill et al., 2005; Vieira et al., 2018). It was well-accepted that 
individuals with low socioeconomic status had greater difficulty in accessing health 
services and consequently prevent factors that could lead to falls (Cruz et al., 2012; Gill 
et al., 2005; Vieira et al., 2018). However, similar to our findings, two population-based 
studies conducted in different countries (Denmark, Indonesian) did not report the 
association between income level and falls or fractures (Bonnerup Vind et al., 2011; 
Pengpid et al., 2018). Further, a systematic review investigating the association between 
socioeconomic status and osteoporotic fractures did not find that lower income level was 
related to higher risk of fractures (Brennan et al., 2009). None of these studies provided 
an explanation for the failure to find association between income level and falls or 
fractures. In our opinion, the lack of association between the income level and fall-related 
injuries could be an indicator of the improving equality of access to health care services 
in the general older adult population in Ontario.  
3.4.1 Strengths and Limitations 
This was a population-based study investigating the association between medication 
prescribed within 30 days of fall-related injury in older adults using province-wide 
(Ontario) administrative health data. The major strengths are provincial 
representativeness and large size with over a million older adults in the case and control 
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groups. The dataset included detailed information on demographics, comorbidities, 
prescribed medication classes, and strictly defined fall-related injuries using ICD-10-CA 
codes. Second, data obtained from IC/ES databases has been recognized to have high 
data completeness (Levy et al., 2003) and high quality (Aiken et al., 2016; Liu et al., 
2018; Macri et al., 2017). Third, due to study’s population-based design, the results can 
be generalized to the entire population of older adults in Ontario, Canada. Fourth, all the 
index events were recorded on the day cases went to the ED because of a fall-related 
injury, so recall bias is minimal. 
Several limitations are associated with this study. First, the algorithm used to match cases 
and controls did not have a fixed ratio and the matching was not successful when groups 
were compared on the matching factors. In response, the multivariable logistic regression 
modeling was adjusted for the matching variables to account for any residual 
confounding. Second, we evaluated only fall-related injuries leading to ED visit, 
therefore these results cannot be generalized to less severe fall-related injuries. Third, 
only prescribed and dispensed drugs were recorded in ODB database, but neither 
prescription nor dispensation can be equated with actual use, which is an unfortunate 
limitation of this type of research. Further, we recorded medications prescribed one 
month prior to a fall-related injury, but we were not able to ascertain whether a 
medication was used for a long-term or it was a new initiation. We believe that the timing 
of medication use is of importance and will address this in our future research. Fourth, 
some comorbidities might be associated with fall-related injuries, but the detailed 
information on indications for prescription was not available in the original databases 
from which we extracted our dataset. Hence, our results could include a degree of 
overestimation of the association between medications and fall-related injuries. What is 
more, confounding by indication was not fully addressed in this study. Confounding by 
indication occurs when selecting a particular intervention also affects the outcome 
(Kyriacou & Lewis, R, 2016; Salas & Stricker, 1999). For example, patients with more 
severe diseases are likely to receive more intensive care and treatment, therefore when 
comparing the interventions, the more intensive intervention will appear to result in 
poorer outcomes. The degree of severity of a disease affects both treatment selection and 
patient outcome and these factors could be related to fall-related injuries. Hence, findings 
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from this study should be viewed with caution. Last but not least, there was a lack of 
indicators for the frailty in both case and control groups. For example, surgeries and other 
medical procedures could substantially but temporarily increase the number of prescribed 
medications in the peri-operative period, which in an administrative dataset might be 
mimicking the frailty. Unfortunately, in this study, we did not have enough information 
to address the impact of frailty on fall-related injuries.      
3.5 Conclusion 
This study examined the association between fall-related injury in older adults and 
medication classes prescribed to them within 30 days prior to the injury. Our findings 
acknowledged persistent association of CNS drugs with the fall-related injuries, and 
provided additional associations between fall-related injury and statins, PPIs, 
antithrombotic agents, laxatives, drugs for benign prostatic hyperplasia, antibiotics, 
biphosphonates, and bronchodilators. Well-designed prospective cohort studies probing 
into the effects of comorbidities, Injury Severity Scores and detailed prescription 
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Chapter 4  
4 Association between Continuous use or New Initiation 
of Medications and Fall-Related Injuries in Older Adults 
4.1 Introduction 
The rapid growth of world aging population and its related challenges have become 
major concern to individuals, families and the societies. It was reported that 20-30% of 
community dwelling older adults aged 65 years or older fall every year (Chang et al., 
2010; Tanimoto et al., 2014; Tinetti et al., 2006; Wu & Ouyang, 2017). Falls are the 
leading cause of non-fatal and fatal injuries for older adults in many countries and regions 
(Bergen et al., 2016; Ellingsen et al., 2018; National Council of Aging, 2018; Public 
Health Agency of Canada, 2014). About 30-50% falls result in minor injuries such as 
bruises, sprains and strains that may or may not require medical treatment, while 5-10% 
of falls lead to serious consequences such as fractures and brain injury (Cameron et al., 
2012; Gillespie et al., 2012; Goldacre et al., 2002; Health Quality Ontario, 2008). Fall-
related injuries can result in decreased independence and quality of life, disability, 
prolonged length of stay in hospitals and increased risk of early admissions to long-term 
care facilities (Burns et al., 2016; Gill et al., 2013, Scott et al., 2010), as well as cause 
substantial economic burden to the public health care system (National Council of Aging, 
2018; Parachute, 2015; Zecevic et al., 2012). It was estimated that about 0.9%-1.5% of 
total health care cost were the fall-related expenses in the US, Europe and Australia 
(Heinrich et al., 2009). Fall-related injuries have become a serious health risk in later life, 
that will continue to grow with an increasing older adult population (He et al., 2016).  
The mechanism of fall-related injuries in older adults is complicated and multifactorial. 
History of falls, old age, mobility and balance problems, and use of psychotropic 
medications and cardiovascular medications were reported to be associated with fall-
related injuries (Gillespie et al., 2012; Mccoy et al., 2017; Nilsson et al., 2016). Most 
importantly, the prescription of medications to older adults increased significantly over 
the last twenty years (Clemens et al., 2015; Craftman et al, 2016; Jackevicius et al., 2009; 
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Minard et al., 2016), further increasing this prominent modifiable risk factor for fall-
related injuries.  
Previous studies have focused mainly on the association of cross-sectional use of certain 
medication classes and fall-related injuries (de Vries et al., 2018; Leipzig et al., 1999a; 
Leipzig et al., 1999b; Seppala, Wermelink, et al., 2018; Seppala, van de Glind, et al., 
2018; Zang, 2013). However, medication initiation, change in dosage and long-term use 
are significant concerns, as are medications’ therapeutic effects and side effects (Barker 
et al., 2004; Engelke et al., 2019; Huybrechts et al., 2011; Hyttinen et al.,2017; 
Schmieder et al., 2009). Daoust and colleagues (2018) reported that opioids use were 
associated with increasing the risk of falls 2.5 times in first two weeks of drug initiation. 
Butt et al. (2013) reported that within 14 days of new initiation of any antihypertensive 
drug were associated with doubled risk of falls (Incidence rate ratio [IRR]= 1.94 and 95% 
Confidence Intervals [CIs] [1.75-2.16]). A recent systematic review reported that chronic 
antihypertensive drug use was not associated with falls, but there was a highly elevated 
risk of falls in the first day after the drug initiation (Kahlaee et al., 2018).  A clear gap in 
the current literature is limited understanding of the association between fall-related 
injuries and new initiation or continuous use of medications. The purpose of this study 
was to explore the association between chronically used or newly initiated medication 
classes and fall-related injury in older adults.  
4.2 Methods 
4.2.1 Study Design  
We conducted a population-based, case-control study using administrative secondary 
health care data for Canada’s most populous province of Ontario. Ontario is the largest 
province in Canada, with a population of 14.7 million and 2.6 million older adults over 
the age of 65 (Statistics Canada, 2020), all of whom have access to universal healthcare 
services. The extraction of eligible participants in this study was conducted by IC/ES 
analysts, based on a carefully prepared data creation plan (DCP, Appendix B). IC/ES is 
an independent, non-profit research institute whose legal status under Ontario’s health 
information privacy law allows it to collect and analyze health care and demographic 
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data. IC/ES is a prescribed entity under the section 45 of Ontario’s Personal Health 
Information Protection Act. Section 45 authorizes IC/ES to collect personal health 
information, without consent, for the purpose of analysis or compiling statistical 
information with respect to the management of, evaluation or monitoring of, the 
allocation of resources to or planning for all or part of the health system. Projects 
conducted under section 45, by definition, do not require review by a Research Ethics 
Board. This project was conducted under section 45, and was approved by IC/ES’ 
Privacy and Legal Office. However, ethics approval for this series of studies was required 
in Western University, and it was obtained from the Research Ethics Board at Western 
University, London, Ontario, Canada (HSREB #109335, detailed information was 
provided in Appendix C).  
4.2.2 Data Sources 
We used records from three databases held by IC/ES: (1) the Ontario Drug Benefit 
(ODB) database, which provides prescription drug coverage data for residents over the 
age of 65, including individuals in long-term care homes (Government of Ontario, 2019); 
(2) the National Ambulatory Care Reporting System (NACRS), which captures 
information on visits to emergency departments (EDs) and community-based ambulatory 
care facilities; and (3) the Ontario Registered Persons Database (RPDB), which contains 
demographic information for Ontario residents. These databases were linked using 
unique encoded identifiers, which ensured the confidentiality of personal and health 
information.  
Age, sex, residence area (i.e., Local Health Integration Networks [LHINs]), and 
neighborhood income quintile were extracted from RPDB dataset. LHINs are the health 
authorities that are responsible for the regional public healthcare service in Ontario, 
Canada. There are 14 LHINs in operation in Ontario (Local Health Integration Networks, 
2020). Neighborhood income quintile is a measure of socioeconomic status that divides 
the population living in same dissemination area into five income groups (1 represents 
the lowest income; 5 represents the highest income) with approximately 20% of the 
population in each group (Canadian Institute for Health Information [CIHI], 2016).  
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4.2.3 Selection of Cases and Controls 
The cases in this case-control study had to fulfill the following criteria: (a) residing in 
Ontario; (b) 66 years and older, (c) visited ED for fall-related injury between January 1, 
2010 and December 31, 2014. The ODB program covers the cost of prescription 
medications for all Ontarians 65 years and older, therefore those under the age of 66 were 
excluded to avoid incomplete medication information in their first year of eligibility. 
Patients who visited an ED for fall-related injury were captured by the NACRS database. 
The ICD-10-CA codes (CIHI, 2018b; World Health Organization [WHO], 2020) were 
used to confirm patients’ diagnosis. Fall-related injury in this study was defined by 
combining the ICD-10-CA codes for falls W00-W19, and codes for injury S00-S99 or 
T00-T14 (Appendix D). The date when the patient was admitted to the ED due to a fall-
related injury was defined as the index date. For individuals who have had multiple 
entries to EDs, only the information of first entry was used. Cases were excluded if they 
had experienced an in-hospital fall-related injury, were transferred from another ED, left 
the ED without being registered, had a scheduled ED visit or died in ED. Controls were 
older adults without a fall-related injury diagnosis extracted from Ontario RPDB, and 
matched to cases by the same age, sex, and LHIN, with no fixed ratio. An index date was 
assigned randomly to each control within the five-year study period. As the authors had 
no access to the database hosted by IC/ES, all of the above operations were completed by 
an IC/ES analyst according to a pre-agreed DCP (Appendix B) to generate the matched 
dataset, which was then provided to the research team. 
4.2.4 Medication Use   
Continuous use or new initiation of a medication class prior to fall-related injury was 
regarded as one of the risk factors for fall-related injuries. Continuous use of a 
medication is operationally defined as more than 90 days of refill of a medication within 
three months prior to a fall-related injury. New initiation of a medication is operationally 
defined as any new prescription of a medication within 30 days prior to a fall-related 
injury. The newly initiated medication must not have appeared in the person’s 
prescription list within 365 days to 31 days prior to the injury. ODB datasets uses Drug 
Identification Numbers (DIN), an eight-digit number, assigned by Health Canada (Health 
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Canada, 2018) to identify different medications. Each DIN included information on 
medication’s manufacturer, trade name, active ingredients, strength of the active 
ingredients, pharmaceutical form, and route of administration (Health Canada, 2018). In 
order to better understand and compare findings of this study with the results of other 
studies, DIN codes were converted to Anatomical Therapeutic Chemical (ATC) level 5 
codes and grouped into 4th level codes. In ATC classification system, each medication is 
classified in a hierarchy with 5 levels (WHO, 2019). The 1st level includes fourteen 
anatomical main groups, these main groups are divided into 2nd level, which is the 
pharmacological or therapeutic group. The 3rd and 4th levels are chemical, 
pharmacological or therapeutic subgroups and the 5th level the chemical substance. ATC 
4th level was used to report continuous use and new initiation of different medications 
because it is the level which aggregates medications just above their descriptive chemical 
substance (Krause, 2008).  
4.2.5 Statistical Analysis 
The difference between case and control groups in characteristics such as age, sex, 
income quintile, LHINs, the number of medication classes prescribed with, presence of 
COPD, asthma, dementia, diabetes and hypertension were evaluated by Wilcoxon rank 
sum test, with an alpha of .01.  Older adults were categorized into three groups, aged 66-
74, 75-84, and 85+.  The number of medication classes prescribed to each older adult 
within 30 days of the fall-related injuries was calculated and classified into one of four 
categories: 0-4, 5-9, 10-14, and 15 or more different medication classes. Number of 
continuous users and new users of each medication class in both case and control group 
were calculated. To ensure the power, only top 30 most frequent medication classes for 
continuous use and for new initiation were included in the regression analysis. Univariate 
logistic regression was used to calculate the crude Odds Ratios (ORs) and 99% 
confidence intervals (CIs) for continuous use or new initiation of each medication class. 
Multivariate logistic regression models were conducted for each included medication 
class, adjusted for sex, age group, LHIN, neighborhood income quintile, and number of 
medication classes prescribed. The corresponding ORs were recorded as adjusted ORs 




This study included 1,005,066 community-dwelling older adults. The case group 
included 255,270 older adults who experienced fall-related injuries over the five-year 
period. The mean age of the cases was 77.7±7.7 years and 61.1% were female. The 
control group included 749,796 older adults, with a mean age of 75.1±7.5 years old and 
54.0% female. The case and control groups were similar in income quintile distribution 
but were significantly different in LHINs, age group constitution, female percentage, and 
number of prescribed medication classes (Table 3.1). 
For medication classes with continuous use, HMG-CoA reductase inhibitor (statin, 
C10AA) was the most commonly prescribed among older adults who experienced fall-
related injuries (Table 4.1). Eight different anti-hypertensive medications were among the 
top 30 medication classes with most common continuous use. Continuous use of 
psychotropic agents such as antidepressants (N06AB and N06AX), benzodiazepine 
derivatives (N05BA), opioids (N02AA) and anticholinesterases (N06DA) were also very 
common. Other medications with continuous use were proton pump inhibitors (A02BC), 
laxatives (A06AA), glucose sugar lowering drugs (A10BA, A10BB), thyroid hormones 
(H03AA) and biphosphonates (M05BA). After adjustment for sex, age group, number of 
medications prescribed, income quintile and residence area (LHINs), continuous use of 
selective serotonin reuptake inhibitors (SSRIs, medication for depression) were 
associated with increasing the odds of fall-related injuries almost by two times 
(aOR=1.96, 99%CI [1.91-2.01]). Other medications that could increase the odds of fall-
related injuries by over 50% were drugs for benign prostate hyperplasia (G04CA and 
G04CB), antithrombin agents (B01AC) and anticholinesterases (N06DA) for treating 
Alzheimer’s disease. Organic nitrates (C01DA) and H2-receptor antagonist (lowering the 




Table 4.1 Association Between Top 30 most Common Medications with Continuous Use and Fall-
related Injury in Older Adults 
ATC code Medication Class 
Number of Users Unadjusted ORs 
(99% CIs) 
Adjusted ORs* 
(99% CIs) Case Control Total 
A02BA H2-receptor antagonists 5,343 13,837 19,180 1.14 [1.10, 1.17] 0.87 [0.83, 0.91] 
A02BC Proton pump inhibitors 48,280 86,250 134,530 1.97 [1.65, 2.34] 1.40 [1.38, 1.42] 
A06AA Softeners, emollients 9,810 13,810 23,620 2.13 [2.08, 2.19] 1.37 [1.32, 1.42] 
A10BA Biguanides 23,371 53,109 76,480 1.32 [1.30, 1.34] 1.17 [1.15, 1.20] 
A10BB Sulfonylureas 12,073 27,299 39,372 1.31 [1.29, 1.34] 1.12 [1.09, 1.16] 
B01AA Vitamin K antagonists 9,422 16,677 26,099 1.69 [1.64, 1.73] 1.22 [1.18, 1.26] 
B01AC Platelet aggregation inhibitors  12,938 19,568 32,506 1.99 [1.95, 2.04] 1.56 [1.51, 1.61] 
B03AD Iron in combination with folic acid 7,720 12,699 20,419 1.81 [1.76, 1.86] 1.19 [1.14, 1.23] 
C01DA Organic nitrates 6,744 14,738 21,482 1.35 [1.32, 1.39] 0.78 [0.75, 0.81] 
C03AA Thiazides, plain 23,513 58,028 81,541 1.21 [1.19, 1.23] 1.10 [1.08, 1.13] 
C03CA Sulfonamides, plain 21,463 39,165 60,628 1.67 [1.64, 1.70] N/A 
C07AB Beta blocking agents, selective 42,537 92,690 135,227 1.42 [1.40, 1.44] 1.18 [1.16, 1.20] 
C08CA Dihydropyridine derivatives 38,097 88,173 126,270 1.35 [1.33, 1.37] 1.15 [1.13, 1.17] 
C08DB Benzothiazepine derivatives 10,318 18,718 29,036 1.65 [1.61, 1.69] 1.34 [1.29, 1.38] 
C09AA ACE inhibitors, plain 48,459 117,654 166,113 1.26 [1.24, 1.27] 1.10 [1.09, 1.12] 
C09CA Agents on RAS 26,181 60,570 86,751 1.30 [1.28, 1.32] 1.17 [1.15, 1.20] 
C09DB ARBs and CCBs 7,274 19,629 26,903 1.09 [1.06, 1.12] 1.13 [1.09, 1.17] 
C10AA HMG CoA reductase inhibitors 85,971 195,116 281,087 1.44 [1.43, 1.46] 1.37 [1.35, 1.39] 








6,811 12,494 19,305 1.62 [1.57, 1.67] 1.66 [1.59, 1.73] 
H03AA Thyroid hormones 34,551 69,421 103,972 1.53 [1.51, 1.56] 1.25 [1.23, 1.28] 
M04AA 
Preparations inhibiting uric acid 
production 
8,050 17,818 25,868 
1.34 [1.30, 1.37] 1.19 [1.14, 1.23] 
M05BA Biphosphonates 16,170 32,050 48,220 1.52 [1.49, 1.55] 1.19 [1.16, 1.22] 
N02AA Natural opium alkaloids 7,693 11,281 18,974 2.04 [1.98, 2.10] 1.34 [1.29, 1.40] 
N05BA Benzodiazepine derivatives 13,724 24,991 38,715 1.65 [1.61, 1.68] 1.18 [1.14, 1.21] 
N06AB SSRIs 20,475 24,259 44,734 2.61 [2.56, 2.66] 1.96 [1.91, 2.01] 
N06AX Other antidepressants 16,001 21,066 37,067 2.31 [2.27, 2.36] 1.62 [1.57, 1.67] 
N06DA Anticholinesterases 11,194 12,913 24,107 2.62 [2.55, 2.69] 1.58 [1.52, 1.64] 
R03BB Anticholinergics 9,885 17,933 27,818 1.65 [1.60, 1.69] 1.27 [1.22, 1.31] 
Note ACE inhibitors: angiotensin converting enzyme inhibitors; RAS: renin-angiotensin system; 
ARBs: Angiotensin II receptor blockers; CCBs: calcium channel blockers; N/A: not available 
* adjusted for sex, age group, income quintile, residence area (Local Health Integration Networks) 








Number of Users Unadjusted ORs 
(99% CIs) 
Adjusted ORs* 
(99% CIs) Case Control Total 
A02BC Proton pump inhibitors  2,010 4,255 6,265 1.39 [1.32, 1.47] 1.08 [1.01, 1.16] 
A06AA Softeners, emollients  1,650 2,559 4,209 1.90 [1.79, 2.02] 1.26 [1.16, 1.37] 
A06AB Contact laxatives 1,555 2,348 3,903 1.95 [1.83, 2.08] 1.30 [1.19, 1.42] 
A06AD Osmotically acting laxatives 1,840 2,789 4,629 1.95 [1.84, 2.07] 1.32 [1.22, 1.43] 
B03AD Iron in combination with folic acid 804 1,501 2,305 1.58 [1.45, 1.72] N/A 
C01DA Organic nitrates  913 1,947 2,860 1.38 [1.27, 1.49] 0.91 [0.82, 1.01] 
C03CA Sulfonamides, plain 1,236 2,103 3,339 1.73 [1.61, 1.86] N/A 
C07AB Beta blocking agents, selective  953 1,719 2,672 1.63 [1.51, 1.77] 1.15 [1.04, 1.28] 
C08CA Dihydropyridine derivatives  758 1,674 2,432 1.33 [1.22, 1.45] N/A 
C09AA ACE inhibitors, plain 938 2,046 2,984 1.35 [1.25, 1.46] N/A 
C09CA agents on the renin-angiotensin system 660 1,431 2,091 1.36 [1.24, 1.49] 1.45 [1.15, 1.84] 
C10AA HMG CoA reductase inhibitors  1,106 2,562 3,668 1.27 [1.18, 1.36] 1.11 [1.01, 1.22] 
H02AB Glucocorticoids  2,542 4,921 7,463 1.52 [1.45, 1.60] 1.17 [1.10, 1.25] 
J01CA Penicillins with extended spectrum  2,385 4,869 7,254 1.44 [1.37, 1.52] 1.24 [1.16, 1.33] 
J01DB First-generation cephalosporins 1,951 2,750 4,701 2.09 [1.98, 2.22] 1.56 [1.44, 1.69] 
J01DC Second-generation cephalosporins  631 1,389 2,020 1.34 [1.22, 1.47] N/A 
J01FA Macrolides  1,945 4,358 6,303 1.31 [1.25, 1.39] 1.08 [1.01, 1.16] 
J01MA Fluoroquinolones  2,931 5,296 8,227 1.63 [1.56, 1.71] 1.13 [1.06, 1.20] 
J01XE Nitrofuran derivatives  1,410 2,093 3,503 1.99 [1.86, 2.13] 1.40 [1.28, 1.54] 
M01AB 
Acetic acid derivatives, related 
substances  
747 1,367 2,114 1.61 [1.47, 1.76] 1.50 [1.33, 1.70] 
M01AE Propionic acid derivatives 1,083 1,863 2,946 1.71 [1.59, 1.85] 1.53 [1.38, 1.70] 
N02AA Natural opium alkaloids  4,409 6,515 10,924 2.01 [1.93, 2.09] 1.58 [1.50, 1.67] 
N05BA Benzodiazepine derivatives  1,523 2,653 4,176 1.69 [1.59, 1.80] 1.17 [1.08, 1.28] 
N06AB Selective serotonin reuptake inhibitors  1,332 1,247 2,579 3.15 [2.91, 3.40] 2.14 [1.93, 2.38] 
N06AX Other antidepressants  1,417 1,417 2,834 2.94 [2.73, 3.17] 1.94 [1.76, 2.15] 
R03BA Glucocorticoids (drugs for COPD)  750 1,815 2,565 1.21 [1.12, 1.32] 0.89 [0.80, 1.00] 




1,757 2,466 4,223 2.10 [1.98, 2.24] 1.49 [1.37, 1.62] 
S01AA Antibiotics-ophthalmologicals  672 1,438 2,110 1.37 [1.25, 1.51] N/A 
S01BA Corticosteroids, plain 985 2,133 3,118 1.36 [1.26, 1.47] 1.17 [1.06, 1.30] 
 
Note. ACE inhibitors: angiotensin converting enzyme inhibitors; COPD: chronic obstructive 
pulmonary disease; N/A: not available 
* adjusted for sex, age group, income quintile, residence area (Local Health Integration Networks) 




Natural opium alkaloids (opioids) were the most commonly new-initiated medications in 
older adults before they had fall-related injuries. Anti-hypertensive agents and 
psychotropic agents were also very common. Interestingly, there were six different 
medications for treatment of infections in the top 30 most commonly new-initiated 
medications (Table 4.2).  New initiation of SSRIs and other antidepressants were 
associated with increasing the odds of fall-related injuries by more than two times 
(SSRIs: aOR=2.14, with 99%CI [1.93-2.38]; other antidepressants: aOR=1.94 with 
99%CI [1.76-2.15]). New initiation of opioids (N02AA), first-generation cephalosporins 
(J01DB), propionic acid derivatives (M01AE), and acetic acid derivatives (M01AB) were 
also associated with increasing the odds of fall-related injuries by over 50%. Except for 
agents acting on renin-angiotensin system (C09CA), new initiation of other 
antihypertensive showed no association or minor association with fall-related injuries.  
4.4 Discussion 
This population-based, case-control study evaluated the association between fall-related 
injuries and 30 most common medication classes for continuous use and medications that 
were newly initiated. Continuous use of antidepressants, drugs for benign prostate 
hyperplasia, anticholinesterases for Alzheimer’s disease, emollients for constipation, and 
antithrombin agents were found to increase the odds of fall-related injuries by over 50%. 
New initiation of antidepressants, opioids, first-generation cephalosporins, non-steroids 
anti-inflammatory drugs (NSAIDs), and laxatives also showed to be associated with 
increased odds for fall-related injuries. 
There is no consensus among researchers on how to define continuous use of a 
medication as it depends on the medication itself. For example, for antibiotics and 
NSAIDs, more than 14 days of use is considered as long-term. For benzodiazepines and 
antidepressants, six months is considered as long-term use (Cartwright et al., 2016; 
Kurko et al., 2015). However, for blood glucose lowering agents and antihypertensive 
drugs, a year is considered as long-term use (Kahlaee et al., 2018). Older adults 
diagnosed with chronic diseases often take medications for years and even remaining 
lifetime (Lornstad et al., 2019; Rossello et al., 2015, Sharma et al., 2015). This study 
applied three months (90 days) period to define “continuous use” of medications, guided 
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by acceptance of this definition in previous studies (Ammerman et al., 2019; Aubron et 
al., 2010; Bargagli et al., 2019; Hart et al., 2019)   
Statins are widely prescribed to older adults with high cholesterol in order to reduce the 
risk of cardiovascular event. In our study, 28.1% older adults used statins for a long-term 
of over three months. This rate was comparable to findings of Wang et al. (2016) who 
reported a chronic statin use rate in 31.4% older adults. The association between 
continuous use of statins and continuous use odds of fall-related injuries in older adults 
was unexpected (aOR=1.37, 99%CI [1.35, 1.39]). Some clinical trials demonstrated that 
statins had a decreased survival benefit in sicker patients, especially among older adults 
with heart failure (Kjekshus et al., 2007) and those undergoing dialysis (Wanner et al., 
2005). However, a systematic review summarized three studies on statin use as an 
exposure to the risk of falls (Seppala, van de Glind, et al., 2018), and reported a pooled 
OR of 0.80 (95%CI [0.65,0.98]). The authors explained that statins’ protective 
association with falls might be explained by statins’ reducing white matter lesion 
progression, thus delaying the balance impairments. However, this meta-analysis did not 
take into consideration the duration of statin use, so further research was recommended 
on the statin use duration in older adults and better differentiation of participants (e.g., 
different age groups or health status). Important distinction here is that our study reports 
association with injuries due to falls, not falls themselves.  
Proton pump inhibitors (PPIs) were prescribed to 32.1% of Canadian older adults in 2016 
(CIHI, 2018b). Although we did not find that new initiation of PPIs were associated with 
increased odds of fall-related injuries, continuous use of PPIs was identified to be 
associated with increasing the odds of injury by 40% (aOR=1.40, 99%CI [1.38-1.42]). 
Lewis et al. (2014) reported that PPI therapy for longer than one year was associated with 
continuous use odds of hip fracture in older adults (aOR=2.04, 95%CI [1.23-3.37]). Yang 
et al. (2006) showed that the strength of the association continuous use with increasing 
duration of PPI therapy (1 year of PPI therapy aOR=1.22, 95% CI, [1.15-1.30]; 2 years, 
aOR=1.41, 95% CI, 1.28-1.56]; and 4 years, 1.59 [95% CI, 1.39- 1.80]; P.001 for all 
comparisons). A possible explanation for why PPIs increase the risk of fracture might be 
that PPIs reduce intestinal calcium and vitamin D absorption and thus might contribute to 
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a decrease in bone mineral density (Dharmarajan et al., 2008). Another mechanism might 
lie in the fact that PPI users were found to have a 18% lower level of Vitamin B12. 
Ample evidence shows that long-term Vitamin B12 deficiency could result in gait 
disorders, muscle weakness, cognitive decline and impaired vision (Lewis et al., 2014; 
Marcuard et al., 1994; Stabler, 2013), all of which are risk factors for fall-related injuries.    
Although researchers have noticed that initiation or continuous use of antihypertensive 
agents were related to falls, studies on the association with fall-related injuries remain 
rare. A systematic review using more than 28 days of medication therapy as continuous 
use reported that continuous use of antihypertensive agents did not increase the risk of 
falls in older adults (Kahlaee et al., 2018). But our study showed that continuous use of 
angiotensin-converting enzyme inhibitors (ACEIs), BBs, dihydropyridine derivatives, 
agents acting on the renin-angiotensin system, thiazides, angiotensin II receptor blocker 
(ARBs) and calcium channel blockers (CCBs) combination were associated with slightly 
increasing the risk of fall-related injuries. Continuous use of benzothiazepine derivatives 
were associated with increasing the odds of fall-related injuries by 34% (aOR=1.34, 
99%CI [1.29-1.38]).  
The Kahlaee et al. (2018) systematic review also reported that new initiation of diuretics, 
BBs, CCBs, and ACEI/ARBs were associated with increased the risk of falls. Another 
population-based study using ODB database to explore the new initiation of 
antihypertensive agents reported that the risk of falls in older adults increased within the 
period of 45 days after new initiation of diuretics, ACEIs, ARBs, CCBs and BBs (Butt et 
al., 2013). The same group of researchers demonstrated that initiation of BBs and ACEIs 
were associated with increased risk of hip fractures in older adults (BBs: aOR=1.58, 
95%CI [1.01-2.48]; ACEIs: aOR=1.53, 95%CI [1.12-2.10]), which was in line with our 
results (Butt et al., 2012). Our findings identified that new initiation of beta-blocking 
agents (BBs) were only associated with a slightly increased risk of fall-related injuries 
(aOR=1.15, 99%CI [1.04-1.28]), while new initiation of agents on the renin-angiotensin 
system were associated with increasing the odds by 45% (aOR=1.45, 99%CI [1.15-
1.84]). The findings of our study provided new evidence on the association between 
continuous use or new initiation of antihypertensive drugs and fall-related injuries in 
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older adults, identifying the need for additional studies to improve the knowledge in the 
future. 
In addition, our findings showed that continuous use of psychotropic agents such as 
selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs) and 
anticholinesterases for treating Alzheimer’s disease in older adults were associated with 
increasing fall-related injuries odds by 60-96%. Continuous use of opioids also was 
associated with increasing the odds by 34% (aOR=1.34, 99%CI [1.29-1.40]). New 
initiation of SSRIs and TCAs were associated with increasing the odds of fall-related 
injuries almost by two times, while continuous use and new initiation of benzodiazepines 
was only slightly associated with increased risk of fall-related injuries. The association 
between psychotropic agents and falls, and fall-related injuries in older adults has been 
studied extensively. A wide range of psychotropic medications such as analgesics, 
antiepileptics, antidepressants, sedatives and hypnotics have been confirmed to relate to 
fall-related injuries (Gray et al., 2020; Seppala, Wermelink, et al., 2018; Seppala, van de 
Glind, et al., 2018), but few studies focused on the association between the time window 
of using a medication and fall-related injuries. Our study findings were consistent with 
Vitry and colleagues (2010), who reported that persistent use of psychotropic medications 
in female older adults was associated with increasing the risk of experiencing hip fracture 
by 2.5 times (RR=2.54, 95%CI [1.57-4.11]). Using medication information from ODB 
database, Liu et al. (1998) reported that new initiation of SSRIs in older adults was 
associated with increasing the odds of hip fracture by 2.4 times (aOR=2.4, 95%CI [2.0-
2.7]), and new initiation of tertiary-amine TCAs were associated with increasing the odds 
of hip fracture by 50% (aOR=1.5, 95%CI [1.3-1.7]). Findings from our study not only 
indicated that new initiation of SSRIs and TCAs were related to fall-related injuries, but 
also that continuous use of SSRIs and TCAs could be associated with increased odds of 
fall-related injuries.  
Very few studies focused on continuous use or new initiation of medication classes other 
than psychotropic agents or antihypertensive agents. Findings from our study, that 
continuous use of two medication classes for treatment of benign prostate hyperplasia 
(G04CA and G04CB), anti-thrombotic agents (B01AA and B01AC) and emollients for 
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constipation (A06AA) was associated with increased risk of fall-related injuries made an 
original contribution to the current knowledge. Our study also showed that new initiation 
of some laxatives (A06AA, A06AB and A06AD), antibiotics (J01CA, J01DB and 
J01XE), NSAIDs (M01AB and M01AE) and selective beta-2-adrenoreceptor agonists 
could increase the risk of fall-related injuries by 30-50%. Further studies need to adjust 
for indications for these medications to provide further evidence on their association with 
fall-related injuries in older adults.   
Most previous studies ascertained medication use in older adults at the baseline or at the 
time of fall or fall-related injuries, without information on whether the medication was 
newly initiated or has been used for a long-term (Leipzig et al., 1999a; Leipzig et al., 
1999b; Seppala, Wermelink, et al., 2018; Seppala, van de Glind, et al., 2018). Findings 
from our study provided evidence about a “window” of opportunity to incorporate 
preventive strategies such as education or closer monitoring over a specific time in the 
pharmacotherapy process.  
4.4.1 Strengths and Limitations 
The major strengths of this population-based study are provincial representativeness and 
large size of over a million observations in case and control groups of older adults. 
Second, the data obtained from IC/ES databases had satisfying data completeness (Levy 
et al., 2003) and high quality as reported consistently in previous studies (Aiken et al., 
2016; Liu et al., 2018; Macri et al., 2017). Third, due to study’s population-based design, 
the results can be generalized to the entire population of older adults in Ontario, Canada. 
Fourth, the recall bias is minimal as all the fall-related injuries were recorded on the day 
cases presented to the ED.  
Several limitations are associated with this study. First, the controls were matched with 
cases by sex, age and residence area (LHIN), but as the matching ratio was not fixed, 
resulting in great imbalance between the case and control group (Table 3.1). We adjusted 
for sex, age group, residence area (LHIN), income quintiles and number of medication 
classes prescribed, in regression analysis so that these imbalances were considered. 
Second, only prescribed and dispensed drugs were recorded in ODB database, but 
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chronic comorbidities and aging-related reduction in cognitive function could lead to low 
adherence to prescribed medications in older adults (Hennein et al., 2018). Hence, neither 
prescription nor dispensation can be equated with actual use. Third, some comorbidities 
might be associated with fall-related injuries, but the detailed information on indications 
for prescription was not available in the original dataset. Hence our results could include 
a degree of overestimation of the association between medication and fall-related injuries. 
What is more, confounding by indication (Kyriacou & Lewis, R, 2016; Salas & Stricker, 
1999) was not fully addressed in this study. For example, patients with more severe 
diseases are likely to receive more intensive care and treatment and when comparing the 
interventions, the more intensive intervention will appear to result in poorer outcomes.  
Hence, findings from this study should be viewed with caution. Fourth, there was a lack 
of indicators on the frailty for both case and control group. For example, surgeries and 
other medical procedures could increase the frailty, accompanied by an obvious 
increasing in the number of medications prescribed during the peri-operation period. But 
in this study, we did not have enough information to address the impact of frailty on fall-
related injuries.   
4.5 Conclusion 
This study examined the association between fall-related injuries in older adults and 
continuous use or new initiation of medication classes prior to the injury. Findings 
revealed that both continuous use and new initiation of particular medication classes were 
associated with fall-related injuries. Namely, continuous use of antidepressants, drugs for 
benign prostate hyperplasia, anticholinesterases for Alzheimer’s disease, emollients for 
constipation and antithrombin agents were found to increase the risk of fall-related 
injuries. New initiation of antidepressants, opioids, first-generation cephalosporins, non-
steroids anti-inflammatory drugs, and laxatives showed to be associated with increased 
risk for fall-related injuries. This evidence suggests existence of a “window” of 
opportunity for application of injury prevention strategies while closely monitoring 
timing in the process of pharmacotherapy. Future research should consider exploration of 
comorbidities and particular indications for prescription to provide more convincing 
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Chapter 5  
5 Discussion 
5.1 Main findings 
The main purpose of this dissertation was: 1) to provide a comprehensive list of 
medication classes prescribed to older adults within one year prior to their fall-related 
injuries, 2) to evaluate the association between fall-related injuries and most frequently 
prescribed medication classes prescribed within 30 days prior to the injuries, and 3) to 
explore association between chronically used and newly initiated medications and fall-
related injury in older adults.  
Study 1, was descriptive to set the stage and help determine research questions for 
consecutives studies. Findings alerted us to the difference between the medication classes 
prescribed to older adults who experienced the fall-related injury and the medication 
classes prescribed to the general population of older adults. To explore further, in Study 
2, we established case control group, recorded the medication classes prescribed to both 
groups, and conducted logistic regression to find out which medications were positively 
related to fall-related injury. Through this project, we recognized the importance of 
initiation and duration of medication use in relation to the fall-related injury. Hence, in 
Study 3, we explored whether the medication classes were prescribed for a long-term or 
were initiated within one month prior to the injury. The associations between continuous 
use or new initiations and fall-related injury were identified by multivariate logistics 
regression. 
The main findings are briefly summarized as follows: 
• Among older adults sustaining any fall-related injury, 48.5% were prescribed 
statins, 34.3% proton pump inhibitors (PPIs), 29.0% angiotensin converting 
enzyme inhibitors (ACEIs), 25.0% opioids, 16.6% benzodiazepine derivatives, 
and 14.7% selective serotonin receptor inhibitors (SSRIs) within one year prior to 
the injury. (Study 1) 
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• Similar patterns of medication prescription were found for fall-related fractures 
and traumatic brain injury. Among older adults who had fall-related fracture, 
45.4% were prescribed statins, 33.1% PPIs, 27.6% ACEIs, 24.5% opioids and 
14.6% SSRIs. Among older adults who had fall-related traumatic brain injury, 
52% were prescribed statins, 35.5% PPIs, 30.3% ACEIs, 24.9% opioids and 
16.5% SSRIs. (Study 1) 
• More than third, 36.4%, of older adults were prescribed 5-9 different medication 
classes and 41.2% were prescribed 10 or more medication classes within one year 
prior to fall-related injury. (Study 1) 
• Consistent with previous studies, we reported that use of laxatives, psychotropic 
agents and anti-inflammation drugs within one month prior to an injury can 
increase the odds of fall-related injury in older adults. (Study 2) 
• Relatively new to the current knowledge is that we identified that statins, drugs 
for benign prostatic hyperplasia, biphosphonates, penicillins with extended 
spectrum, and bronchodilators also were associated with increased risk of fall-
related injury. (Study 2) 
• After adjusting for sex, age group, income level, residence area and number of 
medications prescribed, continuous use (more than 90 consecutive days) of 
statins, PPIs, SSRIs, 𝛼-adrenoreceptor antagonists, platelet aggregation inhibitors 
and anticholinesterases was associated with increasing the odds of fall-related 
injury in older adults by nearly 50%. (Study 3) 
• After adjusting for sex, age group, income levels, residence area and number of 
medications prescribed, new initiation (starting a medication within one month 
prior to a fall-related injury) of opioids, first-generation cephalosporins, selective 
𝛽2-adrenoreceptor agonists, SSRIs and other antidepressants (mostly tricyclic 
antidepressants [TCAs]) was associated with increasing the odds of fall-related 
injury in older adults by 50%. (Study 3) 
It is well established that medications are modifiable risk factors for falls and fall-related 
injuries (de Vries et al., 2018; Leipzig et al., 1999a; Leipzig et al., 1999b; Seppala, 
Wermelink et al., 2018; Seppala, van de Glind et al., 2018; Woolcott et al., 2009). 
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Previous studies reporting medication use in Canadian older adults mainly focused on a 
specific medication class, such as benzodiazepines (Kassam et al., 2006), 
antihypertensive medications (Verma et al., 2018), antihyperglycemic medications 
(Clemens et al., 2015), statins (Minard et al., 2016) and opioids (Sharma et al., 2019), 
already suspected to contribute to fall-related injuries. Very few studies were broader in 
scope and provided an overview of medication use in older adults before they had fall-
related injuries. That is why the Study 1 investigated patterns of medications prescribed 
to older adults within one year prior to a fall-related injury. With this new knowledge we 
are now able to explore the difference in medication use between older adults who 
experienced fall-related injuries and the community dwelling older adults. We chose one-
year lookback window to make Study 1 comparable to CIHI report in 2018 because CIHI 
published a report on medications prescribed to the general population of Canadian older 
adults within the year of 2016 (CIHI, 2018). Compared to the findings for general older 
adults in Ontario in CIHI 2018 report, a higher percentage of older adults who have 
experienced fall-related injury were prescribed with ACEIs (26.2% vs.  29.0%), BBs 
(23.3% vs. 25.9%), opioids (15.4% vs. 25.0%), biphosphonates (9.4% vs. 20.4%), 
benzodiazepine derivatives (10.4% vs. 16.1%), thiazides (15.2% vs. 10.8%) and SSRIs 
(10.5% vs. 14.7%). All these medication classes (except for biphosphonates) were 
previously included in the FRIDs lists (Bauer et al., 2012; the Swedish National board of 
Health and Welfare, 2010; Winter et al., 2016; Zia et al., 2017), which partly supported 
the that these medications were associated with fall-related injuries. Another major 
difference was polypharmacy, of the number of medication classes prescribed within the 
past year.  
The effects of polypharmacy have been repeatedly cited in literature as detrimental due to 
potential for adverse drug reactions and drug-drug interactions, especially with decline in 
hepatic and renal function in aging bodies (Chen et al., 2014; Chung, 2014; Huang et al., 
2012; Rowe, et al., 1976; Tan et al., 2015). According to CIHI report, 39.4% older adults 
were prescribed 5 to 9 different medication classes and 26.5% were prescribed with 10 or 
more different medication classes within the year of 2016. Our Study 1 showed that 
36.4% of older adults who experienced fall-related injury were prescribed 5-9 different 
medication classes and 41.2% were prescribed 10 or more different medication classes 
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within the year prior to the injury. It is impossible to confirm in both studies if these 
medications were prescribed concurrently, nonetheless, the higher number of medication 
classes used by injured older adults is concerning and requires further exploration.  
Associations between medication classes commonly prescribed such as statins, PPIs, 
biphosphonates, antibiotics and fall-related injuries in older adults has not been well 
established (de Vries et al., 2018; Seppala, van de Glind, et al., 2018). Most previous 
studies strictly selected study participants which confined the generalizability of their 
findings. Our Study 2 was a population-based, case-control study which is 
methodologically comparable to the Canadian study by Kelly et al. (2003) and Swedish 
study by Kuschel et al (2015). Both studies were population-based and used 
administrative data to identify a wide range of medication classes associated with fall-
related injury in older adults. Both studies captured medication prescription within 30 
days prior to the fall-related injury. Kelly et al. (2003) used 1997/1998 fiscal year health 
registry data from Alberta, Canada. However, the two studies differ in the adjustments for 
cofounders. Kelly et al. (2003) used sex, age, income, seventeen different medications 
and seventeen different comorbidities (e.g., eye disorder, nutritional deficiencies, 
hypertension, depression, dementia, incontinence, etc.) as confounding factors. They 
found that only narcotic pain killers, anti-convulsants (anti-epileptics), and anti-
depressants were independently associated with an increased risk of sustaining injurious 
falls. The authors acknowledged that taking so many comorbidities into consideration 
was complicated because multiple medication classes could be used in the treatment of 
one comorbidity, while a single medication class could be used to treat multiple 
comorbidities. The real effect of every single medication class on fall-related injuries is 
difficult, if not impossible, to fully address. That is partly the reason why we chose to not 
to take five comorbidities we had data for into consideration as confounders. Instead, we 
used the number of medication classes as an indicator for the possible number of 
comorbidities. The second study, by Kuschel and colleagues (2015), reported twenty 
most commonly prescribed ATC 3rd medication classes and their association with fall-
related injuries using Swedish public health data. They reported that CNS drugs (N02A, 
N02B, N05C and N06A), drugs for peptic ulcer (A02B), constipation drugs (A06A), 
antithrombotic agents (B01A), Vitamin B12 (B03B), Calcium (A12A), and NSAIDs 
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(M01A) were independently associated with fall-related injuries. Consistent with their 
results, our Study 2 found (at ATC 4th level) a positive association between PPIs 
(A02BC), constipation drugs (A06AA, A06AB), anti-thrombotic agents (B01AC, 
B01AE), and NSAIDs (M01AB, M01AE, and M01AH) and fall-related injury. Relatively 
new contribution to the current knowledge from our study are additional medication 
classes such as lipid-lowering agents (statins, C10AA), drugs for benign prostatic 
hyperplasia (G04CA and G04CB), pennicillins with extended spectrum (J01DB), 
biphosphonates (M05BA), and selective 𝛽-2-adrenoreceptor agonists for asthma 
(R03CC) that were positively associated with fall-related injuries in older adults. 
Pharmacologically, it is plausible that statins and drugs for benign prostatic hyperplasia 
could increase the risk of fall-related injuries because these medications were reported to 
induce muscle disorders and cardiovascular side effects such as orthostatic hypotension 
(Curfman, 2017; Lee & Cho, 2018; Sica, 2005). Mechanisms of how antibiotics, 
bisphosphonate and bronchodilators can lead to fall-related injuries need to be explored 
further. Collectively, these studies provide evidence that clinicians should not 
underestimate the risk of fall-related injuries when prescribing some of the most frequent 
medications to older adults. 
Starting a new medication, changing a dosage, or prescribing a medication for a very 
long-term use are significant concerns in pharmacotherapy, as medications’ therapeutic 
effects and side effects are closely related to the initiation and duration of medication use 
(Barker et al., 2004; Engelke et al., 2019; Huybrechts et al., 2011; Hyttinen et al.,2017; 
Schmieder et al., 2009). To explore the association between medication classes and fall-
related injuries, Study 3 identified top 30 most commonly prescribed medications as new 
initiations and for continuous use. Consistent with previous studies (Kahlaee et al., 2018; 
Vitry et al., 2010; Yang et al., 2006), continuous use of antihypertensives, antidepressants 
and proton pump inhibitors (PPIs) were reported to increase the risk of fall-related 
injuries. New initiation of antihypertensives and antidepressants was also associated with 
higher risk of fall-related injuries. What emerged as novel in our findings, was that 
continuous use of two medication classes (G04CA and G04CB) for treatment of benign 
prostate hyperplasia, anti-thrombotic agents (B01AA and B01AC) and emollients for 
constipation (A06AA) were also associated with inceasing the risk of fall-related injuries. 
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For new initiations, our study showed that some laxatives (A06AA, A06AB and 
A06AD), antibiotics (J01CA, J01DB and J01XE), NSAIDs (M01AB and M01AE) and 
selective beta-2-adrenoreceptor agonists could increase the risk of fall-related injuries by 
30-50%. The findings from Study 3 provided evidence about a “window” of opportunity 
for implementation of injury prevention strategies for older adults such as education or 
closer monitoring over a specific time in the pharmacotherapy process.  
The findings of these studies provide clear evidence to support better clinical decisions to 
the family doctors, physicians, geriatricians, pharmacists and other health care 
professionals on association between medication classes and fall-related injury in older 
adults. Previous studies focused predominantly on psychotropic medications and 
antihypertensive agents and their mechanisms on inducing falls in older adults, while our 
studies reported additional medication classes that might be associated with the 
occurrence of fall-related injuries in older adults, such as statins, PPIs, biphosphonates, 
bronchodilators and antibiotics. These medication classes are also among the most 
extensively prescribed ones, so their impact on fall-related injuries should not be 
underestimated or ignored.  
5.2 Clinical Implications and Knowledge Translation 
The main part of this thesis focused on identifying medication classes as risk factors for 
fall-related injuries in older adults. This purpose was in line with World Health 
Organization (WHO) falls prevention strategy on improving the identification and 
assessment of determinants of falls (WHO, 2007) and the Canadian Patient Safety 
Institute’s (CPSI) injury reduction strategy on multifactorial risk assessment and  
individualized interventions for those at high risk of fall-related injuries. In our extensive 
study of medication classes that were associated with fall-related injuries, we identified 
several commonly prescribed medication classes that might contribute to fall-related 
injuries in older adults. In addition to psychotropic agents and medications for 
cardiovascular system disease, other medications such as laxatives, antithrombotic 
agents, antibiotics and bronchodilators were also reported to increase the risk of fall-
related injuries (Study 2). The impact of these medication classes on fall-related injuries 
was rarely studied, yet they are frequently prescribed to older adults. Findings from this 
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thesis provide evidence to family doctors, physicians, geriatricians and pharmacists to 
support their informed decisions about deprescribing or balancing benefits and harms of 
prescribing, should their goal be to lower the risk of fall-related injuries.  
We also reported that the duration of medication use was an important concern to balance 
medications’ therapeutic effects and side effects. In our study, the continuous use of 
antidepressants, drugs for benign prostate hyperplasia, anticholinesterases for 
Alzheimer’s disease, emollients for constipation and antithrombin agents was associated 
with increased risk of fall-related injury. New initiation of antidepressants, opioids, first-
generation cephalosporins, non-steroids anti-inflammatory drugs, and laxatives was also 
associated with increased risk of fall-related injury. This association between timing of 
medication use and fall-related injury provided evidence to clinicians on a time window 
for incorporating intensive monitoring and injury prevention strategies. Medication 
review has been reported to be effective in preventing fall-related injuries both as a single 
intervention (Blalock et al., 2010; Boyé et al., 2016; Sjöberg et al., 2013) or combined as 
a component of multifactorial prevention protocols (Matchar et al., 2017; Mikolaizak et 
al., 2017; Salimen et al., 2009). But the details on the best way to perform medication 
review are still under investigation (American Geriatrics Society, 2019; Huckerby & 
Johal, 2015; Jokanovic et al., 2016). Knowledge from Study 3 provided evidence about 
the opportune time to perform medication review and which medication classes to focus 
on. This knowledge is also of value for older adults and their caregivers, to be more 
vigilant during specific times of pharmacotherapy.  
Calling back to William Haddon’s injury prevention theory (Haddon, 1980; Sattin, 1992), 
this thesis provided evidence for several aspects of injury prevention strategies that 
require more focus. For example, reevaluating the necessity for extensive statin use in 
older adults, especially in the oldest-old age group; enhancing the importance of 
systematic medication review at meaningful time points such as initiation of a new 
medication or after a pre-set period of continuous use; expanding the research to explore 
the association between medication use and fall-related injuries in different age group, for 
different injury types and different duration of medication use; or improving 
individualized prescription for older adults.    
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According to the definition by the Canadian Institutes for Health Research (CIHR), 
knowledge translation is “a dynamic and iterative process that includes synthesis, 
dissemination, exchange and ethically-sound application of knowledge to improve the 
health of Canadians, provide more effective health services and products and strengthen 
the health care system” (CIHR, 2019, “knowledge translation”, para 1).  While 
conducting studies for this thesis, the author identified that all Canadian drugs databases 
use DIN codes and there was no convenient way for quick conversion of DIN codes to 
their chemical names and matching ATC codes. For the purpose of this thesis, over 6,600 
DINs were converted to 305 ATC 4th level codes in accordance with Drug Product 
Database online query Drug Product Database online query (https://health-
products.canada.ca/dpd-bdpp/index-eng.jsp) managed by Health Canada. This website 
contains detailed information about medication’s generic names, ATC codes, DINs, 
dosage, and similar. However, it is burdened with irrelevant information (e.g., approved 
but not on market drugs, off-market drugs), which makes conversion between DIN and 
ATC very difficult. What is more, the main webpage is not user-friendly because it 
contains many search query categories. For a quick reference, direct ATC-DIN or DIN-
ATC conversion would be beneficial. With assistance from a professor and students at 
the Computer Science department at Western University, we designed an innovative, 
user-friendly website for the quick conversion between DINs, ATCs and their chemical 
names. We envision users to be researchers analyzing data from Canadian drug 
databases, pharmacists across Canada, analysts completing big data extractions and 
analysis (e.g., IC/ES, Statistics Canada), students in medical and pharmaceutical schools, 
and graduate students comparing published findings in research papers.  
5.3 Methodological Considerations and Limitations 
It is well-acknowledged that all studies have methodological limitations. The section 
below discusses several most important considerations in epidemiological studies in 
general and specifically how they were addressed in the studies included in this thesis. 
Study 2 and Study 3 were case-control studies. In general, case-control studies begin with 
participants who have the outcome of interest (“cases”) and compare them to participants 
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who do not have the outcome of interest (“controls”). The case-control studies look 
retrospectively to compare how frequently the case and control groups were exposed to a 
risk factor and determine the relationship between the risk factor and outcome of interest 
(Carlson & Morrison, 2009; Schulz & Grimes, 2002).  
5.3.1 Selection of Control Group 
Choosing a control group can greatly affect the case-control study’s vulnerability to bias. 
Control group should arise from the same general population as the cases, and it should 
be similar in every aspect except the outcome of interest (Borgan et al., 2018; Carlson & 
Morrison, 2009; Melamed & Robinson, 2019). The case group in our studies included all 
older adults who were 66 years and older who had experienced a fall-related injury 
between 2010 and 2014. Controls were matched by same age, sex and LHINs (residence 
area). Both cases and controls were community-dwelling older adults in Ontario. This 
ensured that the control group members represent the population at risk of becoming 
cases, independent of the exposure being studied (Schulz & Grimes, 2002). The 
imbalance of sex, age group and residence area (LHINs) in our studies can be explained 
by the cases and controls not being matched with a fixed ratio. Take age group as an 
example (Table 3.1). There were 100,027 cases and 405,127 controls in 66-74 age group, 
the ratio of case and control was 1 to 4.05. However, in the 85 years and older group, the 
ratio of cases and controls was only 1 to 1.86. That is why there was a higher percentage 
of older adults in control group who were 66 to 74 years old than in the case group. 
5.3.2 Measurement of exposure information 
Exposure history in case-control studies was usually ascertained by interviewing the 
participants or analyzing historical medical charts or records. The general concern for 
case-control study is that cases will always be more likely to recall past exposures than 
controls, which increases recall bias. Interviewers of cases tend to investigate more 
thoroughly on exposure history than controls, which is interviewer bias. Exposure history 
in our studies (medications prescribed to older adults) was obtained from ODB database. 
Every older adult 65 years of age or older in Ontario is automatically entered in ODB 
program and this database contains records for every prescription medication filled 
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(Government of Ontario, 2019). A study by Levy et al. (2003) reported an overall error 
rate of 0.7% (95% CI 0.5% to 0.9%) in ODB database suggesting high coding reliability 
and low potential that results of studies using ODB data will be compromised by coding 
accuracy. We believe that the information bias in this study was very low. 
5.3.3 Precision 
The precision is achieved with fewer random errors or random variations present in a 
study. Random errors cannot be avoided completely as they are unknown and 
unpredictable. Sample selection and measurements of key variables can introduce 
random errors (Carlson & Morrison, 2009; Flannelly et al., 2018; Melamed & Robinson, 
2019). An effective approach to minimize random errors is to use large sample size so 
that the general population can be represented to a larger extent by samples. In this study, 
a sample size of over a million individuals was large enough to dilute possible effects of 
random errors. Generally speaking, a large sample-sized study with more balanced group 
(e.g., similar exposed and unexposed individuals) will produce more precise estimates 
(Rothman et al., 2008). Considering that exposure to medications was impossible to be 
very high, our study included the most commonly prescribed medication classes as 
exposures and thus the precision of the estimates was enhanced. For example, the 
exposure rates for statins in case and control group were 21.7% and 13.8%, exposure 
rates for biphosphonates in case and control group were 8.2% and 4.4% respectively. We 
also used narrow 99%CIs for each estimate of association to enhance precision. 
5.3.4 Internal validity 
Validity refers to a lack of systematic errors while precision refers to a lack of random 
errors. Internal validity describes the extent to which a cause-and-effect established in a 
study cannot be explained by other factors. Whether the outcome of interest can be 
attributed to the exposure, and not to other causes is the key issue in assessing the internal 
validity of a study. A confounding variable is a third variable in a study examining the 
cause-and-effect relationship, also known as a confounder or a confounding factor. A 
confounding variable may be related to both the dependent (risks) and independent 
factors (outcomes). It is very important to address confounding bias in case-control 
126 
 
studies (Rothman et al., 2008). Usually, this type of bias can be managed in the research 
design stage by matching or it can be handled in the analysis stage using analytical 
techniques such as stratification or adjustments in logistic regression models (Borgan et 
al., 2018; Carlson & Morrison, 2009; Rothman et al., 2008). In this study, we planned 
carefully in our DCP to match controls with cases by age, sex and residence area 
(LHINs), with a ratio of 1 (cases) to 5 (controls). However, this strict matching protocol 
resulted in unavailability of controls in the Ontario RPD database, so we ad justed for 
these factors in our multivariate logistic regression model. Neighborhood income quintile 
and number of medication classes prescribed were also taken into consideration as 
confounding factors. These were carefully chosen based on previous literature (Ek et al., 
2019; Jin et al., 2017; Johnson et al., 2015; Towne et al., 2017). Still, controlling for all 
confounding factors is impossible in observational studies (Pearce, 2016; VanderWeele, 
2019), thus resulting in residual confounding.  The secondary data that comprised the 
dataset used in studies of this thesis have been originally collected for other purposes, 
such as surveillance of diseases or monitoring the use of public health care resource. 
Here, this administrative data was used here to examine novel research questions. 
Therefore, a lack of information on confounding factors such as participants’ lifestyles, 
environmental factors and comorbidities was inevitable.  
Furthermore, research on medications presents its own challenges. On one hand, it is 
necessary to understand the specific indications for which the medications were 
prescribed, so that the impact of the disease can be separated from the impact of 
medication used for the disease. On the other hand, medications were used to treat a 
specific disease, so the impact of medications and disease were interwoven with each 
other. It is very common that one medication is used for multiple diseases and also that 
one disease could be treated with multiple medications. Another important factor 
involved in medication treatment that was not adjusted for in this thesis is the drug-drug 
interaction. In our population, considerable percentage of older adults were prescribed 
multiple medications. The risk of an adverse drug event has been estimated at 13% for 
two drugs, 58% for five drugs, and 82% for seven or more drugs (Fulton & Allen, 2005). 
It is likely that the increased risk for fall-related injuries might also be related to drug-
drug interactions (Bennett et al., 2014). Practically speaking, it is tremendously difficult 
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to sort out the singular or combined impact of any specific medication or comorbidity 
pairing, especially when we study a wide range of medications. Since we could not fully 
address the confounding factors, the results of our studies need to be viewed with caution. 
5.3.5 External Validity 
External validity, also known as generalizability, is the degree to which the result or 
conclusion could be generalized to other places and at other times (Rothman et al., 2008). 
In our studies, we included over a million community-dwelling older adults in Ontario. 
We believe the study results are generalizable to other places with similar socioeconomic 
levels, lifestyles and health care policies, such as other provinces in Canada, Australia 
and countries of Western Europe.  
5.4 Future Research Directions 
The methodological limitations and limitations of results from our studies suggest several 
future research directions. First, well-designed prospective cohort studies are required to 
provide more convincing results on the association between medications and fall-related 
injuries. More research attention is needed to explore medication classes not reported to 
be associated to fall-related injuries in previous studies. Second, the definition of 
continuous use cannot be generalized. For example, for antihypertensives, use longer than 
three-month is considered chronic, while for antibiotics, use longer than two weeks is 
considered as chronic. Future research needs to determine a medication-specific 
definition of continuous use and identify the optimal time for implementing preventative 
strategies for different medication classes. This could also apply to new initiation of 
different medications as they have different half-lives. Third, except for duration of 
medication use, the dosage of each medication is also important in producing therapeutic 
and side effects. Future studies focused on the dosage of different medications and their 
association with fall-related injuries are necessary. Fourth, as medications’ impacts and 
diseases’ impacts are inextricably bounded up with each other, it is of great importance to 
clarify the strength and limitations of whether to separate the impacts of the two or not 




Nearly one third of community dwelling older adults fall every year and almost one third 
of the falls result in injuries which require medical consultation or treatment. Total 
healthcare system costs of fall-related injuries are high, partly because of the high 
incidence, but also due to the high costs per incident. Fortunately, over the past 30 years 
of research, many modifiable risk factors have been identified, making the fall-related 
injuries in older adults preventable to some extent. However, the complexity of multi-
comorbidities, latent risk of adverse drug reactions, and poor adherence to 
pharmacotherapy in older adults makes it extremely challenging for physicians, 
pharmacist and geriatricians in clinical treatment. From the author’s own experience as a 
physician, the presence of diseases is something real and medications are necessary to 
mitigate the symptoms, improve quality of life and extend life expectancy. When 
prescribing medications to older adults, physicians face a dilemma, potentially increase 
the risk of fall-related injuries by following clinical best practice guidelines to manage 
the disease, or not. With the accumulation of risks, especially in oldest-old, fall-related 
injuries have a potential to change lives of older adults and their families, impose 
unwelcomed clinical, caregiving and economic consequences. Numerous studies, 
guidelines and fall prevention protocols have included lists of fall-risk increasing drugs 
and were available both to clinicians and older adults. But, what about medications not 
included on the list? Are they safe to use without caution? Based on the findings of three 
studies included in this thesis, the answer is no. Our studies offer a comprehensive 
description of medications prescribed to older adults prior to fall-related injuries, identify 
several medication classes that have not been included on FRIDs lists before, and 
demonstrate that both continuous use and new initiation of medications could increase the 
risk of fall-related injuries. Results from this thesis provide new evidence for more 
medication classes that might be associated with fall-related injuries and require further 
attention from both clinicians and researchers. With continued advances in 
pharmacotherapy, ever deepening ethical dilemma is: Where are the limits of acceptable 
risk when adding new medications to clinical treatments? Growing number of older 
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Appendix A  List of Fall Risk-Increasing Drugs 
Drugs that cause high risk of falling 
N02A Opioids 
N05A (excluding Lithium) Antipsychotics 
N05B Anxiolytics 
N05C Hypnotics and sedatives 
N06A Antidepressants 
Drugs that cause orthostatism/hypotension 




C08 Calcium channel blockers 
C09 Agents acting on the renin-angiotensin system 
G04CA Alpha-adrenoreceptor antagonists 
N04B Dopaminergic agents (anti-Parkinson drugs) 




      Appendix B: Data Creation Plan for IC/ES 
Project Initiation 
This Section must be Completed Prior to Project Dataset(s) Creation  
Project Title: The association between selected health indicators, prescription 
medications and serious fall-related injuries in older adults (REVISED 
July 2019) 
Project TRIM number:  
Research Program: DASDAS 
Site: ICES WesternICES Western 
Project Objectives: Insert Project Objectives as listed in the approved ICES Project PIA 
The objective of this study is to investigate the association between 
selected health indicators, prescription medications and serious fall-
related injuries in older adults 
ICES Project PIA Initial 
Approval Date: 
The ICES Employee or agent who is responsible for creating the Project 
Dataset(s) is responsible for ensuring there is an approved ICES 
Project PIA and verifying the date of approval prior to creating the 
Project Dataset(s) 
2017-Jul-12  
Principal Investigator (PI): Aleksandra Zecevic 
Check the applicable box if 
the PI is an ICES 
Student/Trainee 
☐ ICES Student ☐ ICES Fellow ☐ ICES Post-Doctoral 
Trainee     ☐ Visiting Scholar 
Responsible ICES Scientist: Name the Responsible ICES Scientist if the PI is not a Full Status ICES 
Scientist 
 
Project Team Member(s) 
Responsible for Project 
Dataset Creation and/or 
Statistical Analysis and 
date joined (list all): 
All person(s) (ICES Analyst, Appointed Analyst, Analytic 
Epidemiologist, PI, and/or Student) responsible for creating the Project 
Dataset(s) and/or statistical analysis on the Research Analytics 
Environment (RAE) and the date they joined the project must be 
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Other ICES Project Team 
Members and date joined 
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All other Research Project Team Members (e.g., Research 
Administrative Assistants, Research Assistants, Project Managers, 
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 yyyy-mon-dd 
Confirmation that DCP is 
consistent with Project 
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The following individuals must confirm that the ICES Data provided for 
in this DCP is relevant (e.g., with respect to cohort, timeframe, and 
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Author: 
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ICES Project PIA Amendment 
Date Name Amendment 
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DCP Amendment History 
(add additional rows as 
needed): Date DCP 
amended 
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Study Design ☒ Cohort study  ☐ Matched cohort study  ☒ 
Case-control study 
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Criteria 
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T14 and W00-W19 codes) should be included into the dataset to allow 
analysis of injury types.) 
e)  Diagnosed between Jan 1 2006 and Dec 31 2015.   
Control group  
a) Matched to the case group by sex, age Charlson Comorbidity Index 




b) Exclude the patients having serious fall-related injuries (codes 
W00-W19, codes S00-S99 or T00-14) between Jan 1, 2006 and Dec 31, 
2015. 
• The date of visiting Emergency Department due to serious fall-
related injury will be defined as the index event date. 
• For individuals with repetitive serious fall-related injuries during 
the observation period,  the first time and consecutive visits to ED due to 
serious fall-related injury will be taken into account. 
Estimated Size of Cohort  
(if known) 
 
Exclusions (in order) Step Description 
1 Invalid IKN 
2 Incomplete information (e.g,  missing age or missing sex 
information, non-Ontario residents, died before ED visits) 
3 <65 years old at the index event date 
 4 Patients who have experienced in-hospital serious fall-related 
injuries 
 5 Excluding diagnoses that are suspected, questionable, rule out. 
 6 Excluding transferred ED visits. 
 7 Excluding ED visits from which a patient left without being seen. 
 8 Excluding scheduled ED visits. 
 







Accrual Start/End Dates 2006 Jan 1st to 2015 December 31st  
Max Follow-up Date 2017 Jan 1st  
When does observation 
window terminate? 
12 months after the index date 
Lookback Window(s) 12 months (till 2005 Jan 1st)  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
 
Variable Definitions (add additional rows as needed) 
Main Exposure or Risk 
Factor 
For the full list of variables, please refer to Appendix B – Variables 
from NACRS, CIHI-DAD, RAI-HC and ODB.  
Primary Outcome 
Definition 
Serious fall-related injuries (ICD-10 codes W00-W19 combined with 
S00-S99 or T00-T14 ICD-10 codes) 
Look-back Window Observation Window 
Index Event Date 
Accrual Window 
Max Follow-up Date 
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Baseline Characteristics Case and Control: age, sex, Charlson Comorbidity Index score, LHIN 
Other Variables Variables needed from NACRS, CIHI-DAD, RAI-HC and ODB  
databases are provided in attached file (Appendix B).  
IMPORTANT: to reduce number of observations we decided NOT to 








Analysis Plan and Dummy Tables (expand/modify as needed) 
Descriptive Tables (insert or append dummy tables), e.g.: See Appendix C and Appendix D 
Table 1. Baseline characteristics according to primary/secondary exposure 
Descriptive statistics, measures of central tendency and dispersion for continuous variables, and 
frequency tables for categorical variables. Trends in the data across time will also be analyzed.  
Quality Assurance Activities  
RAE Directory of SAS 
Programs 
 
RAE Directory of Final 
Dataset(s) 
The final analytic dataset for each cohort includes all the data required to create the 
baseline tables and run all the models. It should include all covariates for all models 
such as patient risk factors, hospital characteristics, physician characteristics, 
exposure measures (continuous, categorical) and outcomes. It should include 
covariates that were considered but didn’t make the final cut. This would permit an 
analyst to easily re-run the models in the future. 
 
RAE README file available: ☐Yes ☐No 
Date results of quality assurance tools for final dataset shared 
with project team (where applicable): 
 
 %assign yyyy-mon-dd 
 %evolution yyyy-mon-dd 
 %dinexplore yyyy-mon-dd 
 %track / %exclude yyyy-mon-dd 
 %codebook yyyy-mon-dd 
Additional comments:  




Analysis Plan and Dummy Tables (expand/modify as needed) 
Table 3. Covariates (baseline characteristics) according to outcomes: See dummy tables in 
Appendix D 
Statistical Model(s) 
Type of model Cox Proportional Hazard Regression  
Primary independent variable Risk factors mentioned above 
Dependent variable Serious fall-related injuries and death 
Covariates  























Appendix D: ICD-10 codes used in this thesis 
ICD-10 codes for Injuries and Falls 
Falls 
W00 Fall on same level involving ice and snow  
W01 Fall on same level from slipping, tripping and stumbling  
W02 Fall involving skates, skis, sport boards and in-line skates 
W03 Other fall on same level due to collision with, or pushing by, another person  
W04 Fall while being carried or supported by other persons  
W05 Fall involving wheelchair  
W06 Fall involving bed  
W07 Fall involving chair  
W08 Fall involving other furniture  
W09 Fall involving swing  
W10 Fall on and from stairs and steps  
W11 Fall on and from ladder  
W12 Fall on and from scaffolding  
W13 Fall from, out of or through building or structure  
W14 Fall from tree  
W15 Fall from cliff  
W16 Diving or jumping into water causing injury other than drowning or submersion  
W17 Other fall from one level to another  
W18 Fall on same level in or from bathtub  
W19 Unspecified fall  
Injury 
S00-S09 Injuries to the head  
S10-S19 Injuries to the neck  
S20-S29 Injuries to the thorax  
S30-S39 Injuries to the abdomen, lower back, lumbar spine and pelvis  
S40-S49 Injuries to the shoulder and upper arm  
S50-S59 Injuries to the elbow and forearm  
S60-S69 Injuries to the wrist and hand  
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S70-S79 Injuries to the hip and thigh  
S80-S89 Injuries to the knee and lower leg  
S90-S99 Injuries to the ankle and foot  
T00-T07 Injuries involving multiple body regions  
T08-T14 Injuries to unspecified parts of trunk, limb or body region 
Fractures 
S02 Fracture of skill and facial bones  
S12 Fracture of neck 
S22 Fracture of rib(s), sternum and thoracic spines 
S32 Fracture of lumbar spine and pelvis 
S42 Fracture of shoulder and upper arm 
S52 Fracture of forearm 
S62 Fracture at wrist and hand level 
S72 Fracture of femur 
S82 Fracture of lower leg, including ankle 
S92 Fracture of foot, except ankle 
T02 Fractures involving multiple body regions 
T08 Fracture of spine, level unspecified 
T10 Fracture of upper limb, level unspecified 
T12 Fracture of lower limb, level unspecified 
T142 Fracture of unspecified body region 
Traumatic Brain Injury 
S06 intracranial injury 




Appendix E: Anatomical Therapeutic Classifying system 
codes and Drug Identification Number   
A Drug Identification Number (DIN) is a computer-randomly-generated eight-digit 
number assigned by Health Canada to a drug product prior to being marketed in Canada. 
It uniquely identifies all drug products sold in a dosage form in Canada and is located on 
the label of prescription and over-the-counter drug products that have been evaluated and 
authorized for sale in Canada. A DIN uniquely identifies the following product 
characteristics: manufacturer; product name; active ingredient(s); strength(s) of active 
ingredient(s); pharmaceutical form; route of administration. A DIN lets the user know 
that the product has undergone and passed a review of its formulation, labeling and 
instructions for use. A drug product sold in Canada without a DIN is not in compliance 
with Canadian law (Health Canada, 2018). 
The Anatomical Therapeutic Chemical (ATC) Classification is an internationally 
accepted classification system for medicines that is maintained by the World Health 
Organisation (WHO). It is controlled by the WHO Collaborating Centre for Drug 
Statistics Methodology (WHOCC) and was first published in 1976. The WHO assigns 
ATC codes to all active substances contained in medicines based on the therapeutic 
indication for the medicine. Using the ATC code, active substances are classified in 
groups at five different levels according to the organ or system on which they act and 
their therapeutic, pharmacological and chemical properties.   
The first level of the code indicates the anatomical main group and consists of one letter. 
There are 14 main groups. 
Code Contents 
A  Alimentary tract and metabolism 
B  Blood and blood forming organs 
C  Cardiovascular system 
D  Dermatologicals 
G  Genito-urinary system and sex hormones 
H Systemic hormonal preparations, excluding sex hormones and insulins 
J Anti-infectives for systemic use 
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L  Antineoplastic and immunomodulating agents 
M Musculo-skeletal system 
N  Nervous system 
P  Antiparasitic products, insecticides and repellents 
R  Respiratory system 
S Sensory organs 
V  Various 
The second level of the code indicates the therapeutic subgroup and consists of two 
digits. The third level of the code indicates the therapeutic/pharmacological subgroup and 
consists of one letter. The fourth level of the code indicates the chemical/ therapeutic/ 
pharmacological subgroup and consists of one letter. The fifth level of the code indicates 
the chemical substance and consists of two digits. Take metformin as an example: 
Medication information extracted from ODB database are all in DIN codes, so the 
conversion of DINs to ATC codes is necessary for better understanding of the result and 
easy comparison with other publications.  
Level Code Content   
1 A Alimentary tract and metabolism Anatomical main group 
2 A10 Drugs used in diabetes Therapeutic subgroup 
3 A10B Oral blood glucose lowering drugs Pharmacological subgroup 
4 A10BA Biguanides Chemical subgroup 
5 A10BA02 Metformin Chemical substance 
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Appendix F: Table A1 
Table A1 




Female Male Total 
66-74 75-84 85+ Total % 66-74 75-84 85+ Total % No % 
A02BA H2-receptor antagonists 3180 4049 3088 10317 5.7 1762 2309 1380 5451 5.1 15768 5.5 
A02BB Prostaglandins 149 129 73 351 0.2 30 41 24 95 0.1 446 0.2 
A02BC Proton pump inhibitors 20449 25546 19100 65095 35.7 11144 14059 8441 33644 31.7 98739 34.3 
A02BX 
Other drugs for peptic ulcer and 
(GORD) 
313 344 180 837 0.5 143 166 92 401 0.4 1238 0.4 
A03AB 
Synthetic anticholinergics, 
quaternary ammonium compounds 
43 34 73 150 0.1 33 38 24 95 0.1 245 0.1 
A03FA Propulsives 2578 3302 2390 8270 4.5 1151 1443 823 3417 3.2 11687 4.1 
A04AA Serotonin (5HT3) antagonists 556 378 124 1058 0.6 375 333 77 785 0.7 1843 0.6 
A05AA Bile acids and derivatives 101 96 48 245 0.1 38 39 9 86 0.1 331 0.1 
A06AA Softeners, emollients 5198 9364 8785 23347 12.8 3480 5960 4444 13884 13.1 37231 12.9 
A06AB Contact laxatives 4250 7242 6522 18014 9.9 2811 4592 3556 10959 10.3 28973 10.1 
A06AC Bulk-forming laxatives 795 1512 1414 3721 2.0 447 953 816 2216 2.1 5937 2.1 
A06AD Osmotically acting laxatives 4405 6337 6058 16800 9.2 3201 4336 3049 10586 10.0 27386 9.5 
A07AA Antibiotics 1212 1346 850 3408 1.9 559 659 352 1570 1.5 4978 1.7 
A07DA Antipropulsives 654 1082 1198 2934 1.6 391 541 401 1333 1.3 4267 1.5 
A07EA Corticosteroids acting locally 3577 3842 2360 9779 5.4 2007 2473 1338 5818 5.5 15597 5.4 
A07EC 
Aminosalicylic acid and similar 
agents 
210 185 80 475 0.3 115 85 37 237 0.2 712 0.2 
A09AA Enzyme preparations 119 147 103 369 0.2 87 112 41 240 0.2 609 0.2 
A10AB 
Insulins and analogues for 
injection, fast-acting 




Insulins and analogues for 
injection, intermediate-acting 
615 583 298 1496 0.8 503 505 155 1163 1.1 2659 0.9 
A10AE 
Insulins and analogues for 
injection, long-acting 
1979 1558 627 4164 2.3 1999 1430 426 3855 3.6 8019 2.8 
A10BA Biguanides 8771 9660 5014 23445 12.9 7615 7466 2771 17852 16.8 41297 14.3 
A10BB Sulfonylureas 4130 4924 2829 11883 6.5 3924 4141 1762 9827 9.3 21710 7.5 
A10BD 
Combinations of oral blood 
glucose lowering drugs 
418 304 97 819 0.4 398 232 72 702 0.7 1521 0.5 
A10BF Alpha glucosidase inhibitors 172 191 90 453 0.2 142 145 47 334 0.3 787 0.3 
A10BG Thiazolidinediones 651 624 200 1475 0.8 564 495 134 1193 1.1 2668 0.9 
A10BH 
Dipeptidyl peptidase 4 (DPP-4) 
inhibitors 
1779 1697 695 4171 2.3 1650 1339 511 3500 3.3 7671 2.7 
A10BX 
Other blood glucose lowering 
drugs, excl. insulins 
43 79 37 159 0.1 28 51 16 95 0.1 254 0.1 
A11CC Vitamin D and analogues 499 837 629 1965 1.1 458 668 395 1521 1.4 3486 1.2 
B01AA Vitamin K antagonists 2280 5597 5833 13710 7.5 2643 5344 3576 11563 10.9 25273 8.8 
B01AB Heparin group 505 537 323 1365 0.7 371 476 206 1053 1.0 2418 0.8 
B01AC 
Platelet aggregation inhibitors 
excl. heparin 
2830 5263 5008 13101 7.2 3413 4923 3042 11378 10.7 24479 8.5 
B01AE Direct thrombin inhibitors 317 884 809 2010 1.1 381 793 560 1734 1.6 3744 1.3 
B01AF Direct factor Xa inhibitors 758 1037 714 2509 1.4 526 785 486 1797 1.7 4306 1.5 
B01AX Other antithrombotic agents 20 26 16 62 0.0 18 23 13 54 0.1 116 0.0 
B03AD 
Iron in combination with folic 
acid 
3393 5997 5509 14899 8.2 2075 3733 2846 8654 8.2 23553 8.2 
B03BA 
Vitamin B12 (cyanocobalamin 
and analogues) 
2196 3648 3523 9367 5.1 1119 1986 1559 4664 4.4 14031 4.9 
B03BB Folic acid and derivatives 1303 1610 1091 4004 2.2 737 890 559 2186 2.1 6190 2.1 
B03XA Other antianemic preparations 75 141 83 299 0.2 43 106 63 212 0.2 511 0.2 
B05AA 
Blood substitutes and plasma 
protein fractions 




Solutions affecting the 
electrolyte balance 
426 484 245 1155 0.6 318 379 174 871 0.8 2026 0.7 
B05XA Electrolyte solutions 15 25 16 56 0.0 7 9 9 25 0.0 81 0.0 
C01AA Digitalis glycosides 779 2358 3301 6438 3.5 892 1812 1525 4229 4.0 10667 3.7 
C01BC Antiarrhythmics, class Ic 185 245 131 561 0.3 90 128 64 282 0.3 843 0.3 
C01CA 
Adrenergic and dopaminergic 
agents 
36 83 32 151 0.1 50 108 51 209 0.2 360 0.1 
C01DA Organic nitrates 3102 5853 6997 15952 8.8 2937 4645 3545 11127 10.5 27079 9.4 
C02AB Methyldopa 60 105 118 283 0.2 25 41 25 91 0.1 374 0.1 








171 324 277 772 0.4 155 270 129 554 0.5 1326 0.5 
C03AA Thiazides, plain 9338 12533 9169 31040 17.0 4603 5321 2940 12864 12.1 43904 15.2 
C03BA Sulfonamides, plain 1769 2527 1806 6102 3.4 1148 1518 781 3447 3.2 9549 3.3 
C03CA Sulfonamides, plain 5460 10254 13402 29116 16.0 4101 7758 6709 18568 17.5 47684 16.5 
C03DA Aldosterone antagonists 1204 1821 1921 4946 2.7 1055 1478 957 3490 3.3 8436 2.9 
C03DB Other potassium-sparing agents 629 832 632 2093 1.1 219 251 191 661 0.6 2754 1.0 
C03EA 
Low-ceiling diuretics and 
potassium-sparing agents 
1189 1600 1349 4138 2.3 342 468 331 1141 1.1 5279 1.8 
C04AD Purine derivatives 114 221 240 575 0.3 142 237 136 515 0.5 1090 0.4 
C07AA 
Beta blocking agents, non-
selective 
857 1126 884 2867 1.6 545 681 418 1644 1.5 4511 1.6 
C07AB Beta blocking agents, selective 11055 18228 15896 45179 24.8 9634 12649 7206 29489 27.8 74668 25.9 
C07AG Alpha and beta blocking agents 400 641 521 1562 0.9 541 821 444 1806 1.7 3368 1.2 
C07BB 
Beta blocking agents, selective, 
and thiazides 
180 234 128 542 0.3 80 67 35 182 0.2 724 0.3 
C07CA 
Beta blocking agents, non-
selective, and other diuretics 
21 38 29 88 0.0 10 14 9 33 0.0 121 0.0 
C08CA Dihydropyridine derivatives 11153 17993 15951 45097 24.8 7725 9698 5722 23145 21.8 68242 23.7 
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C08DA Phenylalkylamine derivatives 240 357 298 895 0.5 144 162 96 402 0.4 1297 0.4 
C08DB Benzothiazepine derivatives 2993 4920 4251 12164 6.7 1870 2522 1499 5891 5.6 18055 6.3 
C09AA ACE inhibitors, plain 13192 18661 15763 47616 26.1 12529 15070 8356 35955 33.9 83571 29.0 
C09BA ACE inhibitors and diuretics 1985 2166 1370 5521 3.0 1604 1344 581 3529 3.3 9050 3.1 
C09CA 
agents acting on the renin-
angiotensin system 
9578 13183 9416 32177 17.7 5568 6204 2923 14695 13.8 46872 16.3 
C09DA 
Angiotensin II receptor blockers 
(ARBs) and diuretics 
3124 3452 2029 8605 4.7 1747 1451 508 3706 3.5 12311 4.3 
C09DB 
ARBs and calcium channel 
blockers 
832 832 451 2115 1.2 471 391 144 1006 0.9 3121 1.1 
C10AA HMG CoA reductase inhibitors 27117 33976 20398 81491 44.7 21800 24490 
1190
4 
58194 54.8 139685 48.5 
C10AB Fibrates 972 1162 467 2601 1.4 852 703 236 1791 1.7 4392 1.5 
C10AC Bile acid sequestrants 437 532 460 1429 0.8 189 246 157 592 0.6 2021 0.7 
C10AD Nicotinic acid and derivatives 74 65 14 153 0.1 132 90 28 250 0.2 403 0.1 
C10AX Other lipid modifying agents 2878 3148 1170 7196 4.0 2601 2442 707 5750 5.4 12946 4.5 
C10BX 
HMG CoA reductase inhibitors, 
other combinations 
481 681 442 1604 0.9 442 508 206 1156 1.1 2760 1.0 
D01AA Antibiotics 305 404 393 1102 0.6 150 180 117 447 0.4 1549 0.5 
D01AC 
Imidazole and triazole 
derivatives 
3499 4741 4472 12712 7.0 1862 2453 1767 6082 5.7 18794 6.5 
D01AE Other antifungals for topical use 1257 1299 969 3525 1.9 1091 1116 676 2883 2.7 6408 2.2 
D05AX 
Other antipsoriatics for topical 
use 
509 391 198 1098 0.6 444 353 140 937 0.9 2035 0.7 
D06AX Other antibiotics for topical use 3713 5171 5205 14089 7.7 2433 3659 2758 8850 8.3 22939 8.0 
D06BX Other chemotherapeutics 645 620 341 1606 0.9 245 275 119 639 0.6 2245 0.8 
D07AA Corticosteroids, weak (group I) 3848 5128 4542 13518 7.4 2120 3029 2199 7348 6.9 20866 7.2 
D07AB 
Corticosteroids, moderately 
potent (group II) 
971 1099 773 2843 1.6 474 616 378 1468 1.4 4311 1.5 
D07AC 
Corticosteroids, potent (group 
III) 




Corticosteroids, very potent 
(group IV) 
1366 1317 789 3472 1.9 612 754 393 1759 1.7 5231 1.8 
D07XC 
Corticosteroids, potent, other 
combinations 
200 198 177 575 0.3 121 146 97 364 0.3 939 0.3 
D10AF 
Antiinfectives for treatment of 
acne 
58 31 8 97 0.1 43 48 14 105 0.1 202 0.1 
D10AH 
Antiinfectives for treatment of 
acne  
79 78 66 223 0.1 49 47 20 116 0.1 339 0.1 
G01AG Triazole derivatives 195 157 83 435 0.2 N/A N/A N/A N/A 0.0 440 0.2 
G03BA 3-oxoandrosten (4) derivatives 6 4 3 13 0.0 541 370 118 1029 1.0 1042 0.4 
G03CA 
Natural and semisynthetic 
estrogens, plain 
2917 2596 1530 7043 3.9 N/A N/A N/A 7 0.0 7050 2.4 
G03HA Antiandrogens, plain 2 1 0 3 0.0 31 96 82 209 0.2 212 0.1 
G03XA 
Antigonadotropins and similar 
agents 
482 585 390 1457 0.8 12 10 6 28 0.0 1485 0.5 
G03CA 
Natural and semisynthetic 
estrogens, plain 
2917 2596 1530 7043 3.9 N/A N/A N/A 7 0.0 7050 2.4 
G03HA Antiandrogens, plain 2 1 0 3 0.0 31 96 82 209 0.2 212 0.1 
G03XA 
Antigonadotropins and similar 
agents 
482 585 390 1457 0.8 12 10 6 28 0.0 1485 0.5 
G04BD 
Drugs for urinary frequency and 
incontinence 








N/A N/A N/A N/A 0.0 3031 4997 3357 11385 10.7 11389 4.0 
H02AB Glucocorticoids 10186 11888 8114 30188 16.6 6354 7872 4605 18831 17.7 49019 17.0 
H03AA Thyroid hormones 12594 16233 13300 42127 23.1 2769 4286 3574 10629 10.0 52756 18.3 
H03BA Thiouracils 60 72 58 190 0.1 14 26 8 48 0.0 238 0.1 
H04AA Glycogenolytic hormones 80 98 85 263 0.1 72 84 36 192 0.2 455 0.2 




Penicillins with extended 
spectrum 




571 669 691 1931 1.1 439 583 379 1401 1.3 3332 1.2 
J01CR 
Combinations of penicillins, 
incl. beta-lactamase inhibitors 
1500 1419 1137 4056 2.2 1024 1038 570 2632 2.5 6688 2.3 
J01DB First-generation cephalosporins 18 31 21 70 0.0 15 15 13 43 0.0 113 0.0 
J01DC 2nd-generation cephalosporins 1764 2008 1704 5476 3.0 1037 1343 815 3195 3.0 8671 3.0 
J01DD 3rd-generation cephalosporins 297 445 379 1121 0.6 207 253 197 657 0.6 1778 0.6 
J01EA Trimethoprim and derivatives 116 213 193 522 0.3 57 101 65 223 0.2 745 0.3 
J01EE Intermediate-acting sulfonamides 2985 4057 3695 10737 5.9 1350 1864 1217 4431 4.2 15168 5.3 
J01FA Macrolides 8142 7044 4229 19415 10.7 4178 4042 2096 10316 9.7 29731 10.3 
J01FF Lincosamides 1726 1740 976 4442 2.4 973 970 497 2440 2.3 6882 2.4 
J01GB Other aminoglycosides 14 21 11 46 0.0 9 18 N/A 31 0.0 77 0.0 
J01MA Fluoroquinolones 7489 9948 8864 26301 14.4 4765 6388 4268 15421 14.5 41722 14.5 
J01XA Glycopeptide antibacterials 20 34 21 75 0.0 9 22 12 43 0.0 118 0.0 
J01XD Imidazole derivatives 1515 1550 866 3931 2.2 872 860 423 2155 2.0 6086 2.1 
J01XE Nitrofuran derivatives 5186 7225 5696 18107 9.9 751 1310 1047 3108 2.9 21215 7.4 
J01XX Other antibacterials N/A N/A N/A 14 0.0 8 N/A N/A 13 0.0 27 0.0 
J02AB Imidazole derivatives 25 23 16 64 0.0 42 39 26 107 0.1 171 0.1 
J02AC Triazole derivatives 159 144 78 381 0.2 81 99 41 221 0.2 602 0.2 
J04AK Other drugs for tuberculosis 16 17 12 45 0.0 6 12 N/A 22 0.0 67 0.0 
J04AM 
Combinations of drugs for 
treatment of tuberculosis 
33 43 39 115 0.1 22 36 16 74 0.1 189 0.1 
J05AB Nucleosides and nucleotides  887 1001 714 2602 1.4 466 556 272 1294 1.2 3896 1.4 
J05AF 
Nucleoside and nucleotide 
reverse transcriptase inhibitors 
36 12 N/A 52 0.0 64 18 N/A 87 0.1 139 0.0 
J05AH Neuraminidase inhibitors 262 1017 2450 3729 2.0 219 535 778 1532 1.4 5261 1.8 
L01AA Nitrogen mustard analogues 46 111 56 213 0.1 49 89 41 179 0.2 392 0.1 
L01AB Alkyl sulfonates 108 90 28 226 0.1 33 23 N/A 56 0.1 282 0.1 
L01BA Folic acid analogues 1047 1046 431 2524 1.4 366 339 149 854 0.8 3378 1.2 
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L01BC Pyrimidine analogues 63 83 14 160 0.1 31 46 20 97 0.1 257 0.1 
L01XE Protein kinase inhibitors 43 48 12 103 0.1 37 39 14 90 0.1 193 0.1 
L01XX Other antineoplastic agents 75 156 147 378 0.2 52 91 64 207 0.2 585 0.2 




N/A N/A N/A N/A 0.0 487 1269 1087 2843 2.7 2844 1.0 
L02BA Anti-estrogens 243 291 230 764 0.4 10 30 30 70 0.1 834 0.3 
L02BB Anti-androgens N/A N/A N/A N/A 0.0 225 684 675 1584 1.5 1586 0.6 
L02BG Aromatase inhibitors 978 971 514 2463 1.4 N/A N/A N/A 10 0.0 2473 0.9 
L03AA Colony stimulating factors 98 45 15 158 0.1 31 26 6 63 0.1 221 0.1 
L04AA Selective immunosuppressants 240 175 46 461 0.3 202 105 15 322 0.3 783 0.3 
L04AB 
Tumor necrosis factor alpha 
(TNF-α) inhibitors 
108 90 28 226 0.1 33 23 N/A 56 0.1 282 0.1 
L04AD Calcineurin inhibitors 270 169 97 536 0.3 203 160 62 425 0.4 961 0.3 
L04AX Other immunosuppressants 189 139 62 390 0.2 101 91 24 216 0.2 606 0.2 
M01AE Propionic acid derivatives 4491 3622 1766 9879 5.4 2570 1973 748 5291 5.0 15170 5.3 
M01AH Coxibs 3717 3891 2288 9896 5.4 1698 1729 778 4205 4.0 14101 4.9 
M03BX Other centrally acting agents 1119 850 306 2275 1.2 566 412 135 1113 1.0 3388 1.2 
M04AA 
Preparations inhibiting uric acid 
production 
1240 2250 1920 5410 3.0 2683 3815 2010 8508 8.0 13918 4.8 
M05BA Biphosphonates 14187 21354 15912 51453 28.2 1867 3299 2316 7482 7.1 58935 20.4 
M05BX 
Other drugs affecting bone 
structure and mineralization 
446 896 679 2021 1.1 14 35 28 77 0.1 2098 0.7 
N02AA Natural opium alkaloids 15408 17873 12311 45592 25.0 10350 10711 5437 26498 25.0 72090 25.0 
N02AB Phenylpiperidine derivatives 608 922 877 2407 1.3 334 407 237 978 0.9 3385 1.2 
N02AJ 
Opioids in combination with 
non-opioid analgesics 
13685 15531 10035 39251 21.6 9283 9555 4712 23550 22.2 62801 21.8 
N02BA Salicylic acid and derivatives 1351 2294 1931 5576 3.1 1239 1785 1078 4102 3.9 9678 3.4 
N03AA Barbiturates and derivatives 164 172 89 425 0.2 134 133 58 325 0.3 750 0.3 
N03AB Hydantoin derivatives 716 710 437 1863 1.0 713 666 311 1690 1.6 3553 1.2 
N03AE Benzodiazepine derivatives 2372 1967 1049 5388 3.0 1060 916 369 2345 2.2 7733 2.7 
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N03AF Carboxamide derivatives 538 491 284 1313 0.7 377 308 130 815 0.8 2128 0.7 
N03AG Fatty acid derivatives 603 340 153 1096 0.6 432 278 90 800 0.8 1896 0.7 
N03AX Other antiepileptics 3036 3026 1889 7951 4.4 1638 1656 757 4051 3.8 12002 4.2 
N04AA Tertiary amines 64 47 21 132 0.1 65 49 6 120 0.1 252 0.1 
N04BA Dopa and dopa derivatives 924 1653 1001 3578 2.0 1023 1971 860 3854 3.6 7432 2.6 
N04BB Adamantane derivatives 102 74 16 192 0.1 97 103 13 213 0.2 405 0.1 
N04BC Dopamine agonists 742 719 400 1861 1.0 455 514 189 1158 1.1 3019 1.0 
N04BD Monoamine oxidaseB inhibitors 24 29 14 67 0.0 38 37 11 86 0.1 153 0.1 
N04BX Other dopaminergic agents 91 119 39 249 0.1 117 176 48 341 0.3 590 0.2 
N05AA Phenothiazines-aliphatic sidechain 168 111 75 354 0.2 124 102 56 282 0.3 636 0.2 
N05AB Phenothiazines piperazine structure 899 855 373 2127 1.2 537 487 160 1184 1.1 3311 1.1 
N05AC Phenothiazines piperidine structure 79 98 52 229 0.1 24 15 7 46 0.0 275 0.1 
N05AD Butyrophenone derivatives 182 349 416 947 0.5 179 319 222 720 0.7 1667 0.6 
N05AH 
Diazepines, oxazepines, 
thiazepines and oxepines 
2178 3160 3404 8742 4.8 1431 1993 1413 4837 4.6 13579 4.7 
N05AN Lithium 295 194 78 567 0.3 187 97 18 302 0.3 869 0.3 
N05AX Other antipsychotics 778 1585 2049 4412 2.4 562 958 789 2309 2.2 6721 2.3 
N05BA Benzodiazepine derivatives 10302 13766 10602 34670 19.0 4420 5446 3334 13200 12.4 47870 16.6 




4182 4347 2208 10737 5.9 1452 1437 695 3584 3.4 14321 5.0 
N06AB 
Selective serotonin reuptake 
inhibitors 
9510 11206 9084 29800 16.4 4198 5191 3221 12610 11.9 42410 14.7 
N06AG 
Monoamine oxidase A 
inhibitors 
50 41 12 103 0.1 28 24 7 59 0.1 162 0.1 




145 99 72 316 0.2 104 88 32 224 0.2 540 0.2 
N06DA Anticholinesterases 1295 6300 7831 15426 8.5 997 3746 3319 8062 7.6 23488 8.1 
N07AA Anticholinesterases 47 47 29 123 0.1 30 50 25 105 0.1 228 0.1 
N07AB Choline esters 48 57 46 151 0.1 28 53 44 125 0.1 276 0.1 
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N07BA Drugs used in nicotine dependence 237 48 N/A 288 0.2 196 43 N/A 240 0.2 528 0.2 
P03AC Pyrethrines 90 141 217 448 0.2 63 82 77 222 0.2 670 0.2 
R01AD Corticosteroids (nasal preparations) 3002 2786 1547 7335 4.0 1577 1726 876 4179 3.9 11514 4.0 
R02AX Other nasal preparations 32 33 21 86 0.0 21 19 7 47 0.0 133 0.0 
R03BA Glucocorticoids (drugs for COPD) 4821 4940 3189 12950 7.1 2184 2743 1522 6449 6.1 19399 6.7 








9090 9039 6065 24194 13.3 4754 5607 3227 13588 12.8 37782 13.1 
S01AA Antibiotics-ophthalmologicals 2063 2660 2028 6751 3.7 1127 1658 1080 3865 3.6 10616 3.7 
S01AD Antivirals-ophthalmologicals 68 61 45 174 0.1 45 53 36 134 0.1 308 0.1 
S01AE Fluoroquinolones 76 100 96 272 0.1 43 63 63 169 0.2 441 0.2 
S01BA Corticosteroids, plain 3520 4958 2405 10883 6.0 1919 2855 1334 6108 5.8 16991 5.9 
S01BC Antiinflammatory agents,  1240 1800 811 3851 2.1 694 1121 460 2275 2.1 6126 2.1 
S01EA Sympathomimetics in glaucoma  707 1336 1315 3358 1.8 496 945 669 2110 2.0 5468 1.9 
S01EB Parasympathomimetics 71 152 251 474 0.3 46 83 98 227 0.2 701 0.2 
S01EC Carbonic anhydrase inhibitors 1022 1975 2204 5201 2.9 677 1377 1031 3085 2.9 8286 2.9 
S01ED Beta blocking agents 909 1681 1946 4536 2.5 503 1002 820 2325 2.2 6861 2.4 
S01EE Prostaglandin analogues 2491 4673 5003 12167 6.7 1475 2805 2221 6501 6.1 18668 6.5 
S01FA Anticholinergics 162 198 177 537 0.3 172 214 126 512 0.5 1049 0.4 
S01GX Other antiallergics 792 988 591 2371 1.3 321 404 235 960 0.9 3331 1.2 
S01HA Local anesthetics 139 98 58 295 0.2 110 89 27 226 0.2 521 0.2 




421 487 266 1174 0.6 253 308 171 732 0.7 1906 0.7 
V06DC Carbohydrates 9727 11013 5692 26432 14.5 7991 8510 3329 19830 18.7 46262 16.0 











Aug 2003 - Jun 2014 
Transplantation Department of Tianjin First Center Hospital, Tianjin, China  
Position title: Attending Physician 
Responsibilities: clinical diagnosis and treatment in the ICU of Transplantation 
Department; patients’ administration pre and post-transplantation; treatment of 
anti-infection, anti-rejection, acute renal failure, cardiac cerebral function 
protection, nutrition, and surgery complications prevention for patients with liver, 
kidney, heart, liver-kidney combined, and pancreas-kidney combined 
transplantations; participate in number of clinical research programs related to the 
perioperative period of organ transplantation; participate in compiling and 
translating of medicine-related documentation. 
Sep 2014-Apr 2020 
Western University, London, Ontario 
Position title: Graduate Teaching Assistant 
Responsibilities: Assist faculty or other instructional staff in postsecondary institutions 
by performing teaching or teaching-related duties, such as teaching lower level courses, 
developing teaching materials, preparing and giving examinations, and grading 
examinations or papers. 
Publications 
Li, D., Yuan, W., Ma, X.T., Cai, H., Ming, Y., Li, J., Zhao, C. H. (2003). The extraction, 
purification and function research of human recombinant fusion protein 
IL6/IL2. High Technology Letters,(11), 27-30. 
Sep 1996 - Jul 2003 
Nankai University, Tianjin, China           
7-year Undergraduate and Graduate Joint 
Program  
Major: Clinical Medicine 
GPA: 84% 
Degree: Master’s Degree of Internal 
Medicine 
 
Sep 2014 - present 
Western University, Ontario, Canada  
Major: Health and Aging, Health and 
Rehabilitation Sciences 
Course Average: 83 
Admitted to master program, transferred 
to PhD program in Sep 2015, take a 
maternity leave from Apr 2016-Mar 2017 
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Wang, Y., Liu, Y.H., Zheng, W.P., Ming, Y., Shen, Z.Y. (2006). Study on risk factor for 
early postoperative infection after orthotopic liver transplantation in adults. 
Chinese Critical Care Medicine. (7). 406-408 
Shen, Z.Y., Liu, Y.H., Wang, Y., Liu, L., Ming, Y. (2006). Management of nutritional 
support and stress hyperglycemia after Orthotopic Liver Transplantation, 
Chinese Critical Care Medicine. (10),599-602.  
Shen, Z.Y., Liu, Y.H., Wang, Y., Liu, L., Ming, Y. (2007). Alteration in serum Cytokines of 
patients with Multiple Organ Dysfunction Syndrome after Liver 
Transplantation. Chinese Critical Care Medicine. (19), 28-30.  
Liu, L., Liu, Y.H., Shen, Z.Y., Yu, L.X., Wang, Y., Ming, Y. (2008). Early postoperative 
treatment for 4 Heart Transplantation patients, Chinese Critical Care Medicine. 
19(7), 438-439.  
Ming, Y., (2011). Application/Comparison on PCT and CRP in Testing Bacterial 
Infection, Jilin Medical Journal,32(30), 248-249. 
Wang, Y., Liu, Y.H., Ming, Y., Liu, L. (2013). Perioperative liquid management for 36 
adult Liver-Kidney Combined Transplantation patients, Chinese Critical Care 
Medicine. (25)7,432-434.  
Ming, Y., & Zecevic, A. (2018). Medications & Polypharmacy Influence on Recurrent 
Fallers in Community: a Systematic Review, Canadian Geriatrics Journal. 21(1),  
14-25. 
Ming, Y., Zecevic, A., Hunter, W. S., Miao, W., & Tirona, R. (2020). The Effectiveness of 
Medication Review on Prevention of Fall-Related Injuries in Older Adults: A 
Systematic Review and Meta-Analysis. Canadian Geriatrics Journal, submitted 
on Jun 29th, 2020. 
Ming, Y., Zecevic, A., Booth, R., Hunter, Tirona, R. & Johnson, A. (2020). Medication 
prescribed within One Year prior to Fall-related Injuries in Ontario Older 
Adults. Canadian Journal on Aging, submitted on Oct 7th, 2020. 
Ming, Y., Zecevic, A., Booth, R., Hunter, Tirona, R. & Johnson, A. (2020). Association 
between Fall-related Injury and Medication Prescribed to Older Adults within 
One Month prior to the Injury. Clinical Intervention on Aging, submitted on Sep 
9th, 2020. 
Presentations 
Ming Y, Zecevic A. (2016). The influence of different classes of medications and 
polypharmacy on elderly recurrent fallers in community: A Systematic 
literature review. Watch Your Step! National Fall Prevention Conference, 
Calgary, Canada.  
Ming Y, Zecevic A. (2016). The influence of different classes of medications and 
polypharmacy on elderly recurrent fallers in community: A Systematic 
literature review. The Gerontological Society of America's 2016 Annual 
Scientific Meeting, New Orleans, United States.  
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Ming Y, Zecevic A, Hunter S, Miao W, Tirona R. (2018). The Effectiveness of Medication 
Review on Prevention of Fall-Related Injuries in Older Adults: A Systematic 
Review and Meta-Analysis. The Gerontological Society of America's 2018 
Annual Scientific Meeting, New Boston, United States.  
Ming Y, Zecevic A, Hunter S, Miao W, Tirona R.  (2019). The Effectiveness of 
Medication Review on Prevention of Fall-Related Injuries in Older Adults: A 
Systematic Review and Meta-Analysis. The 48th Annual Scientific and 
Education Meeting of Canadian Association on Gerontology, Moncton, New 
Brunswick, Canada.  
Ming Y, Zecevic A, Booth R, Hunter S, Tirona R, Johnson A. (2020). Medication 
Prescribed to Older Adults within One Year prior to a Fall-related Injury. 
Accepted as Poster section in the Gerontological Society of America's 2020 
Annual Scientific Meeting.  
Ming Y, Zecevic A, Booth R, Hunter S, Tirona R, Johnson A. (2020). Medication 
Prescribed to Older Adults within One Year prior to a Fall-related Injury. 
Digital Presentation at Connecting Communities: Fall Prevention Across the 
Lifespan. Canadian Fall Prevention Virtual Conference 2020. 
Awards and Funding 
▪ New Techniques Award from Tianjin Health Bureau  
Title: “Pre-operation Application of Protein A Immunoadsorption in the 
Treatment of Sensitized Recipients of Kidney Transplantation.”  
Project conducted in 2013, and the award received in May 2014 
Responsibilities: in charge of study design, data collection and sorting, case 
selection and visiting, and project application. 
▪ Western University of Health Sciences Mid-Career Stimulus Grant  
May 2017-April 2018 (Completed) 
Funding Sources: Western University of Health Sciences  
Principal Applicant: Aleksandra Zecevic Co-investigator: Yu Ming 
▪ Ontario Graduate Scholarship 
Sep 2018-Aug 2019 (Awarded) 
Certificates 
▪ SAS Certified Base Programmer for SAS9 (Nov, 2018) 
▪ SAS Certified Advanced Programmer for SAS9 (Jan, 2019) 
 
 
 
